Compositions and methods to enhance survival and function of transplanted cells in central nervous system applications
Engineering midbrain dopaminergic progenitor cells with TNF-sensitive receptors and using a hydrogel to combat inflammation enhances their survival and function in Parkinson's disease treatment, addressing high mortality rates and phenotypic drift.
Patent Information
- Application Number
- PCT/US2026/028053
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-13
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for Parkinson's disease, such as Levodopa and cell transplantation using induced pluripotent stem cells, face limitations due to high mortality rates of transplanted midbrain dopaminergic neurons from inflammation, primarily caused by the pro-inflammatory cytokine TNF-α, necessitating improved methods to enhance cell survival and function.
Engineering midbrain dopaminergic progenitor cells to express TNF-sensitive receptors that activate transgenes, such as TNF antagonists, and using a hydrogel to protect and present ligands, enabling the cells to combat inflammation and maintain phenotypic stability.
The engineered cells can survive and mature in the inflammatory CNS environment, producing therapeutic proteins and maintaining dopaminergic lineage identity, thereby improving transplantation success and therapeutic efficacy.
Smart Images

Figure IMGF000070_0001_TABLE 
Figure 00000095_0000 
Figure 00000096_0000
Abstract
Description
DESCRIPTIONCOMPOSITIONS AND METHODS TO ENHANCE SURVIVAL AND FUNCTION OF TRANSPLANTED CELLS IN CENTRAL NERVOUS SYSTEM APPLICATIONSPRIORITY CLAIM
[0001] This application claims benefit of priority to U.S. Provisional Application Serial No. 63 / 805,055, filed May 13, 2025, the entire contents of which are hereby incorporated by reference.REFERENCE TO A SEQUENCE LISTING
[0002] This application contains a Sequence Listing XML, which has been submitted electronically and is hereby incorporated by reference in its entirety. Said Sequence Listing XML, created on 05 / 13 / 2026, is named VBLTP0364WO.xml and is 13,754 bytes in size.BACKGROUND1. Field of the Disclosure
[0003] The present disclosure relates generally to the fields of medicine, pathology and neurodegenerative disease. More particularly, the disclosure relates to composition and methods for treating Parkinson’s disease.2. Background
[0004] Parkinson’s disease (PD) is a pervasive and damaging neurodegenerative disease, affecting more than 10 million worldwide, with treatment costs totaling to nearly $52 billion a year in the U.S. The main cause of Parkinson’s disease is the death of dopamine producing cells, midbrain dopaminergic (mDa) neurons, in the brain. Current treatments involve Levodopa, a dopamine precursor medication that helps to replace this vital neurotransmitter, but over time, this medication loses its effectiveness. To address this, researchers have begun investigating transplantion of mDa neurons derived from induced pluripotent stem cells (iPSCs) to replace disease-related neuron loss. This strategy has shown promise, but up to 90% of mDa neurons die within a week after transplantation due to inflammation caused by the transplantation process. A major cause of this is increased susceptibility of mDa neurons to the pro-inflammatory cytokine TNF-a (TNF). Thus, improved methods for treating PD are very much in need.14921-5119-9043, V. 2SUMMARY
[0005] The present disclosure provides an engineered iPSC-derived midbrain dopaminergic (mDA) progenitor cell that expresses one or more artificial TNF-sensitive receptors, wherein activation of the TNF-sensitive receptor results in expression of a transgene. In certain configurations, the transgene encodes a TNF antagonist.
[0006] In some configurations, the artificial TNF-sensitive receptor is a regulated intramembrane proteolysis (RIP) receptor. Representative RIP receptors include a synthetic Notch (synNotch) receptor and a synthetic intramembrane proteolysis receptor (SNIPR). In certain configurations, the TNF antagonist comprises soluble TNF receptor 1 (sTNFRl) or an anti-TNF binding domain. In further configurations, the anti-TNF binding domain comprises a TNF-binding domain derived from ozoralizumab, certolizumab, or adalimumab.
[0007] The disclosure further provides engineered iPSC-derived mDA progenitor cells in which the transgene encodes a fate-stabilizing factor. In certain configurations, the fate-stabilizing factor comprises a WNT ligand, NURR1, or SOX6.
[0008] In some aspects, the engineered iPSC-derived mDA progenitor cell further comprises an additional artificial receptor activated by a ligand integrated in a hydrogel. In certain configurations, the hydrogel-integrated ligand comprises GFP, dimeric GFP, or a GFP -derived ligand. In some configurations, the artificial receptor activated by the hydrogel-integrated ligand comprises an extracellular domain comprising a GFP-binding agent. Representative GFP-binding agents include LaG16 or LaG17. In certain configurations, activation of the artificial receptor by the ligand integrated in the hydrogel results in expression of a fate-stabilizing factor.
[0009] The disclosure also provides an implantable device comprising a plurality of the engineered iPSC-derived mDA progenitor cells described herein. In some configurations, the device comprises a hydrogel associated with the plurality of engineered iPSC-derived mDA progenitor cells, and the hydrogel comprises the cells encapsulated within, seeded into, or entrapped within the hydrogel. In certain configurations, the hydrogel comprises a granular hydrogel comprising hydrogel microparticles, and the plurality of engineered iPSC-derived mDA progenitor cells is seeded into or entrapped within an interstitial pore network of the granular hydrogel microparticles.24921-5119-9043, v. 2
[0010] In some configurations, the hydrogel comprises a ligand integrated in the hydrogel, wherein the ligand is conjugated to, immobilized on, embedded in, or entrapped within the hydrogel. In certain configurations, the ligand comprises GFP, dimeric GFP, or a GFP -derived ligand, and the ligand activates an artificial receptor expressed by the engineered iPSC-derived mDA progenitor cells. In some configurations, the hydrogel has a size or ligand functionalization selected to enhance viability of the engineered iPSC-derived mDA progenitor cells after transplantation and activation of a RIP receptor expressed by the engineered iPSC-derived mDA progenitor cells.
[0011] In further configurations, the hydrogel is degradable, and degradation of the hydrogel reduces activation of the artificial receptor activated by the ligand integrated in the hydrogel. In some configurations, degradation of the hydrogel is timed to correspond to maturation of the engineered iPSC-derived mDA progenitor cells.
[0012] The disclosure further provides a method of delivering the engineered iPSC-derived mDA progenitor cell to a subject comprising implanting the implantable device described herein into the subject. In certain configurations, the subject suffers from Parkinson’s disease.
[0013] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” The word “about” means plus or minus 5% of the stated number.
[0014] It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Other objects, features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the disclosure, are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.34921-5119-9043, v. 2BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0016] FIGS. 1A-D. (FIG. 1A) Staining for the mDa neuron progenitor markers, OTX2, FOXA2, LMXIA, and EN1, for engineered mDa neurons with and without treatment with 50 ng / mL of TNF. A DAPI nuclear counterstain is included for visualization of cells. LMXIA and EN1 markers were stained and imaged in separate wells. (FIG. IB) mCherry reporter activation of engineered mDa neurons exposed to TNF. Neurons are engineered with a constitutive BFP marker for ease of visualization. (FIG. 1C) Engineered mDa neurons treated with TNF show a significant increase in reporter firefly luminescence compared to control engineered neurons. (FIG. ID) Therapeutic protein, sTNFRl, production is significantly increased in engineered mDa neurons treated with TNF. Scale bar = 200 pm. (**p<0.01, Student's t-test with Welch's correction).
[0017] FIGS. 2A-B. Identification that synNotch can detect multimeric inputs independent of previously reported capture -detection schemes required for synNotch activation by monomeric inputs. (FIG. 2A) Firefly luminescence normalized to viability indicating synNotch activation in response a panel of synNotch receptors targeted to TGF -1, TNF, IL-ip and IL-6. (FIG. 2B) Firefly luminescence normalized to ligand-free conditions indicating Anti-GFP synNotch activation in response to varied doses of monomer versus mutant dimer EGFP. Depicted significance indicated compares -i-Dimer vs. +Monomer at respective dose.
[0018] FIG. 3. Material-independent VEGF synNotch signaling. L929 fibroblasts engineered with anti-VEGF synNotch demonstrate ligand dependent activation when supplemented with 25 ng / mL of VEGF. Firefly luminescence readout normalized to cell viability. A Welch’s t test of significance was performed. n=3 for all experimental groups **p<0.01.
[0019] FIG. 4. KOLF2.1J iPSC dimeric EGFP (dEGFP) activation. dEGFP dose response in KOLF 2.1 J human induced pluripotent stem cells (iPSCs) engineered with a GFP-responsive LaG16 synNotch receptor and an inducible mCherry fluorescent protein payload.44921-5119-9043, v. 2Cells were activated with O-lOOOnM of dEGFP for 48 hours before being fixed and immunolabeled for mCherry expression and the nuclear marker DAPI. Cells were imaged and mean mCherry pixel intensity was quantified using ImageJ software. Error bars indicate SEM. n = 15, 5 images from 3 individual wells.
[0020] FIGS. 5A-B. Optimizing the TNF-sensitive synthetic receptor. (FIG. 5A) Luminescence across a range of TNF concentrations normalized to engineered MSCs with no TNF added. (FIG. 5B) Luminescence across a range of TNF concentrations normalized to engineered MSCs with no TNF added. In all plots, n=3 replicates; error bars indicate SEM.
[0021] FIGS. 6A-B. Attenuating inflammation with the optimized TNF-sensitive synthetic receptor. (FIG. 6 A) Schematic of experimental design. NF-KB reporter MSCs were engineered with and without a TNF3E-SNIPR and exposed to TNF. When the NF-KB inflammatory pathway is activated by TNF stimulation, the engineered cells will fluoresce green. The inventors hypothesized that those expressing the TNF3E-SNIPR will demonstrate a reduction in GFP fluorescence, as the synthetic receptor will be able to bind and neutralize the TNF in the environment. (FIG. 6B) Left: Median fluorescence intensity of GFP of reporter MSCs with and without the TNF3E-SNIPR exposed to either 0, 25, or 50 ng / mL of TNF. MSCs with 0 ng / mL of TNF are not significant compared to TNF3E-SNIPR reporters exposed to 25 or 50 ng / mL of TNF (****p<0.0001 by two-way ANOVA with Tukey’s post-hoc test). N=3 replicates; error bars indicate SEM. Right: Representative histograms of TNF3E-SNIPR reporter or reporter MSCs exposed to either 25 or 50 ng / mL of TNF.
[0022] FIGS. 7A-C. Differentiated mDa neurons can be productively engineered with synthetic receptors and activated with a native inflammatory cytokine. (FIG. 7A) Schematic depicting the timeline of differentiation, reverse transduction, and TNF-a treatment. (FIG. 7B) Microscopy images of engineered mDa neurons demonstrating productive mCherry fluorescence in the presence of activating TNF-a. Cells are also engineered with a constitutive BFP marker, demonstrating effective lenti viral transduction. (FIG. 7C) Engineered mDa neurons with and without TNF-a treatment show expression of mDa progenitor markers. Cells are counterstained with a DAPI nuclear stain. LMX1 A and EN1 were stained in separate wells. Scale bar = 200 |xm.54921-5119-9043, v. 2
[0023] FIGS.8A-C. Optimization of mDa differentiation protocol. (FIG. 8A) Timeline of differentiation protocols. E6 transition refers to the original protocol shown in FIG. 7A. Kim, el al. refers to the original protocol introduced in 2021. Maintenance media follows the Kim et al. protocol, but with an additional day as cells are plated in maintenance media on Day 1. (FIG. 8B) Staining for mDa progenitor markers across all three protocols. A DAPI nuclear stain is included for visualization of cells. LMX1A and EN1 were stained in separate wells. Scale bar = 200 pm. (FIG. 8C) Gene expression of mDa progenitor markers quantified through qRT-PCR. Y-axis is logarithmic scale. N=4 replicates; error bars indicate SEM (****p<0.0001, by three-way ANOVA with Tukey’s post-hoc test). Unless otherwise indicated, gene expressions between different protocols are not statistically significant.
[0024] FIGS. 9A-C. Optimization of reporter activation. (FIG. 9A) Microscopy images of mDa progenitors engineered with either the TNF3E-synNotch or the TNF3E-SNIPR with and without TNF. Engineered cells contain a constitutive BFP marker for ease of visualization. Activation is indicated by mCherry fluorescence. Scale bar = 200 pm. (FIG. 9B) Firefly luminescence of engineered mDa progenitors titrated with different percentages of lentivirus for reverse transduction. All conditions are statistically significant from each other (****p<0.0001) except for the -TNF groups which are not significant compared to each other. N=4 replicates; error bars indicate SEM (****p<0.0001, by two-way ANOVA with Tukey's post-hoc test). (FIG. 9C) Fluorescence microscopy showing mCherry transgene output as as a result of TNF treatment of cells engineered using varied amounts of virus. Scale bar = 200 pm.
[0025] FIGS. 10A-C. mDa progenitors can be engineered to produce therapeutic proteins and reduce inflammatory marker expression. (FIG. 10 A) Schematic of extended timeline for mDa differentiation. mDa progenitors are allowed to mature in late neuron media for 5 days before 72 hours of TNF treatment. (FIG. 10B) mDa progenitors significantly upregulate production of sTNFRl in response to TNF treatment. N=4 replicates; error bars indicate SEM. **p<0.01 by Welch’s t test. (FIG. 10C) qRT-PCR gene expression profiling of the neuroinflammatory marker CCL2. Reporter mDas are engineered to produce mCherry while therapeutic mDas are engineered to produce sTNFRl. Different letters indicate statistically significant differences by one-way ANOVA with Tukey’s post-hoc test. N=3 replicates; error bars indicate SEM.64921-5119-9043, v. 2
[0026] FIGS. 11A-B. KOLF2.1J cells engineered via piggyBac transposase / transposon allows for sustained expression of SNIPR through mDA progenitor differentiation protocol and TNF-mediated activation. (FIG. HA) Flow cytometry analysis of myc-tagged SNIPR in WT control or SNIPR-engineered iPSCs or mDA progenitors differentiated for 16 days. (FIG. 1 IB) TNF-activation of SNF-responsive SNIPR after 11 days of differentiation of iPSCs to mDA progenitors.
[0027] FIG. 12. Validation of synNotch activation via GelMA-GFP in 2D. Representative brightfield and mCherry fluorescence images of GelMA plus soluble GFP, 370 nM GelMA-GFP, and 1850 nM GelMA-GFP. Scale bars = 100 pm.
[0028] FIG. 13. GFP conjugation to HMPs and ability to activate synNotch-iPSCs. (A) Fluorescence microscopy confirms conjugation of GFP to HMPs. (B) Activation of synNotch-iPSCs with 1850 nM GFP-HMPs as indicated by mCherry fluorescence. Scale bars = 100 pm.
[0029] FIG. 14. The adapted mDA differentiation protocol used in the studies outlined below.
[0030] FIG. 15. Vector design and dox-driven activation of inducible NURR1 and mCherry or of SOX6 and BFP, as demonstrated by fluorescence microscopy of reporter transgene expression or by qRT-PCR of for the target, fate -promoting transcription factor transgene at day 16 of differentiation.
[0031] FIG. 16. Gene expression profiling by qRT-PCR at the day 30 time point of differentiation for markers of mDA fate in unmodified (WT) KOLF2.1J hiPSCs or KOLF2.1J hiPSCs engineered for dox-inducible expression of NURR1 or SOX6.
[0032] FIG. 17. Immunofluorescence and quantified results at the day 30 time point of unmodified (WT) KOLF2.1J hiPSCs or KOLF2.1J hiPSCs engineered for dox-inducible expression of NURR1 or SOX6 probing for expression of tyrosine hydroxylase (TH).74921-5119-9043, v. 2DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
[0033] As discussed above, Parkinson’s disease is significant health concern around the world. Unfortunately, the available treatments, while effective, all have limitations. Here, the inventors present an approach to ameliorate mDa neuron death by engineering them with TNF-sensitive synthetic receptors to combat inflammatory TNF in the environment through production of therapeutic proteins, like cytokine antagonists.
[0034] These and other aspects of the disclosure are set out in detail below and in the accompanying attachments.I. Compositions and Methods
[0035] The inventors have developed a means for encouraging survival and phenotypic stability of cells transplanted to the central nervous system (CNS). Often, the cellular graft is lost because of inflammation that drives cell death. Further, the transplant microenvironment exposes cells to deleterious factors that cause their specialized functions to be disrupted as their gene expression profile drifts from that of the functions the cells are intended to replace. Here, the inventors disclose a technique that exploits artificial signaling mediated by a synthetic receptor to enable cells to combat inflammation associated with such transplantation procedures. The inventors also disclose a method that enables cells to express genes that support phenotypic stability.
[0036] The disclosure is particularly relevant to a prospective cell-based therapy for Parkinson’s disease (PD). PD involves the loss of a subset of neurons called midbrain dopaminergic (mDA) neurons. Ongoing human clinical trials involve human pluripotent stem cell (hPSC) -derived mDA neuron precursors. These mDA precursors are transplanted to the brain of Parkinson's patients. It has become increasingly appreciated that inflammatory signaling from tumor necrosis factor (TNF) causes these cells to die. Further, evidence that these cells cease to develop along the trajectory of mature mDA neurons is increasing, as well. Thus, methods to enable the mDA neuron precursors to (1) survive in the pro-inflammatory microenvironment and (2) maintain their developmental trajectory once removed from well-controlled culture conditions and transplanted to the host injection site are needed. The methods seek to solve both these problems by a two-faceted engineering approach. First, the inventors engineer mDA precursors to express artificial receptors that allow the cells to recognize selected inputs. These input ligands can be natural factors (like pro-inflammatory cytokines)84921-5119-9043, v. 2or orthogonal, bioinert cues (like green fluorescent protein or fluorescein). Second, the inventors provide a hydrogel material that acts to both protect the cells from physical disruption associated with transplantation and that can also be functionalized to present ligand to cells as they engraft. This hydrogel also incorporates a cell adhesion peptide to enhance neuron viability and neurite projections. Thus, an embodiment of the disclosure pertains to an engineered mDA progenitor that expresses an artificial receptor. In a further embodiment, this engineered mDA progenitor cell can engage with a designer biomaterial that supports maturation and presents ligand to stimulate the artificial receptor to activate a transcriptional program that specifies the phenotype of the mDA cell.
[0037] Here, the inventors employ a class of artificial receptors that activate via Regulated Intramembrane Proteolysis (RIP). Artificial RIP receptors include the synthetic Notch (synNotch) receptor and the SyNthetic Intramembranous Proteolysis Receptor (SNIPR) platform. Inspired from natural receptors such as Notch, these receptors are proteolytically cleaved after engagement with ligand. This cleavage event releases the intracellular domain of the receptor, which then translocates to the nucleus and acts as a transcription factor to regulate target transgene expression. By programming receptor extracellular domains with selected recognition motifs specific for targets of interest (e.g., single chain variable fragments [scFvs] or nanobodies), synthetic RIPs can produce user-specified sense and response behaviors. RIPs such as synNotch and SNIPRs can drive expression of any transgene, making it possible to tune defined cellular responses to selected inputs. This facilitates coupling of orthogonal ligands or pathological microenvironmental cues to engineered cell behaviors. Here, the inventors use RIPs that recognize TNF and GFP to stimulate cells to express transgenes of choice, e.g., those that antagonize inflammation and support development and maturation of mDA phenotype from stem cell-derived mDA progenitors.
[0038] The present disclosure provides pharmaceutical compositions. Such compositions comprise a prophylactically or therapeutically effective amount of a composition, or a peptide immunogen, and a pharmaceutically acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal,94921-5119-9043, v. 2vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a particular carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
[0039] The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical agents are described in “Remington's Pharmaceutical Sciences.’’ Such compositions will contain a prophylactically or therapeutically effective amount of the composition, preferably in purified form, together with a suitable amount of carrier to provide the form for proper administration to the patient. The formulation should suit the mode of administration, which can be oral, intravenous, intraarterial, intrabuccal, intranasal, nebulized, bronchial inhalation, intra-rectal, vaginal, topical or delivered by mechanical ventilation.
[0040] Such compositions can be formulated for parenteral administration, e.g., formulated for injection via the intradermal, intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. Administration by intradermal and intramuscular routes are contemplated. The vaccine could alternatively be administered by a topical route directly to the mucosa, for example by nasal drops, inhalation, by nebulizer, or via intrarectal or vaginal delivery. Pharmaceutically acceptable salts include the acid salts and those which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.104921-5119-9043, v. 2
[0041] Generally, the compositions of the disclosure are supplied either separately or mixed in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
[0042] The compositions of the disclosure can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.IL Parkinson’s Disease
[0043] Parkinson’s disease is a progressive neurodegenerative disorder of the central nervous system characterized, in part, by dysfunction and loss of dopamine-producing neurons in the brain. The disease is commonly associated with impaired movement, including tremor, bradykinesia, rigidity, gait impairment, postural instability, and difficulty with coordinated voluntary movement. Parkinson’s disease may also involve non-motor manifestations, including sleep disturbances, autonomic dysfunction, mood changes, cognitive changes, sensory changes, fatigue, constipation, and other neurologic or systemic features. The clinical presentation and rate of progression may vary among subjects, and symptoms may differ in onset, severity, distribution, and response to therapy.
[0044] A principal neuropathologic feature of Parkinson’s disease is degeneration or dysfunction of dopaminergic neurons in the midbrain, including dopamine-producing neurons located in the substantia nigra. Dopamine is a neurotransmitter involved in communication between neuronal circuits that regulate smooth and purposeful movement. Loss or impairment of dopaminergic neurons reduces dopamine signaling to downstream brain regions, including striatal circuitry, thereby disrupting basal ganglia pathways involved in motor control. The resulting decrease in dopaminergic tone contributes to the motor features commonly associated with Parkinson’s disease, including slowed movement, stiffness, tremor, and impaired balance.114921-5119-9043, v. 2
[0045] The substantia nigra includes dopaminergic neuronal populations that project to striatal regions involved in initiation, modulation, and execution of movement. In Parkinson’s disease, progressive loss of these neurons diminishes dopaminergic innervation and alters signaling within motor control circuits. Although motor dysfunction is a prominent clinical feature, Parkinson’s disease is not confined to motor circuitry. Degeneration or dysfunction of additional neuronal populations and neurotransmitter systems may contribute to non-motor symptoms, including autonomic, cognitive, sensory, psychiatric, and sleep-related manifestations. The disease therefore reflects a complex neurodegenerative process that can affect multiple neural systems while maintaining a central association with degeneration of midbrain dopaminergic neurons.
[0046] Parkinson’s disease has also been associated with intracellular protein aggregates comprising alpha-synuclein, often referred to as Lewy bodies or Lewy pathology. Such aggregates may be observed in affected neurons and are considered a pathologic feature of the disease. The mechanisms contributing to dopaminergic neuron vulnerability and degeneration may include protein aggregation, mitochondrial dysfunction, oxidative stress, altered proteostasis, inflammatory signaling, impaired cellular homeostasis, genetic susceptibility, environmental factors, aging-related changes, or combinations thereof. The relative contribution of such mechanisms may differ among subjects and disease stages.
[0047] Current therapeutic approaches for Parkinson’s disease may provide symptomatic benefit by increasing dopaminergic signaling, modulating neurotransmitter pathways, or altering activity of neural circuits involved in movement. Such approaches include administration of dopamine precursors, dopamine agonists, inhibitors of dopamine metabolism, other pharmacologic agents, and surgical or device-based interventions that modulate brain circuitry. These approaches may improve motor symptoms or quality of life in certain subjects, but they generally do not replace the dopaminergic neurons lost during disease progression. Over time, pharmacologic approaches may become less effective, may produce fluctuating responses, or may be associated with adverse effects. Accordingly, there remains a need for therapeutic strategies that address loss or dysfunction of dopaminergic neurons and support durable restoration or preservation of dopaminergic function.
[0048] Cell replacement strategies have been investigated as a means to provide new dopaminergic lineage cells for subjects having Parkinson’s disease. Human pluripotent stem124921-5119-9043, v. 2cells, including induced pluripotent stem cells, can be differentiated into midbrain dopaminergic precursor or progenitor cells that are capable of further maturation toward dopamine-producing neurons. Such cells may be delivered to a target region of the central nervous system to provide a cell population capable of surviving, maturing, extending processes, integrating with host tissue, producing or regulating dopamine-associated functions, or otherwise contributing to restoration of dopaminergic signaling. The use of induced pluripotent stem cell-derived midbrain dopaminergic progenitor cells provides a renewable and engineerable cellular source for transplantation-oriented approaches.
[0049] A challenge associated with cell replacement for Parkinson’s disease is the survival and functional persistence of transplanted dopaminergic lineage cells after delivery. Transplanted cells may encounter mechanical stress, altered trophic support, hypoxia, immune-mediated injury, inflammatory cytokines, and other hostile features of the post-transplant microenvironment. A substantial fraction of transplanted dopaminergic lineage cells may die soon after transplantation, thereby reducing engraftment efficiency and limiting the therapeutic potential of the cell product. In addition, cells removed from controlled culture conditions and placed into a host tissue environment may experience signals that alter maturation, reduce lineage stability, or disrupt acquisition of a desired midbrain dopaminergic phenotype.
[0050] Inflammation is a particularly relevant feature of the transplantation microenvironment. Delivery of cells into the central nervous system can produce local injury responses and inflammatory signaling. Tumor necrosis factor (TNF) is one inflammatory mediator associated with cell stress and death in dopaminergic lineage cells. TNF-mediated signaling may contribute to reduced survival of transplanted midbrain dopaminergic progenitor cells and may also interfere with maturation or maintenance of a desired dopaminergic lineage state. Thus, approaches that allow transplanted cells to sense inflammatory cues and respond locally may improve survival, reduce inflammatory injury, and promote persistence of cells intended to replace or supplement dopaminergic function.
[0051] The present disclosure addresses these limitations by providing engineered induced pluripotent stem cell-derived midbrain dopaminergic progenitor cells configured to respond to one or more cues associated with the post-transplant environment. Such cells may be engineered to detect TNF or another inflammatory signal and to express a therapeutic transgene, such as a TNF antagonist, in response to that signal. The cells may also be134921-5119-9043, v. 2configured to express factors that support survival, maturation, or stabilization of midbrain dopaminergic lineage identity. In this manner, the engineered cells may be better suited to withstand inflammatory and environmental stresses encountered after transplantation while maintaining characteristics appropriate for Parkinson’s disease cell replacement therapy.
[0052] The disclosure further recognizes that cell survival and maturation after transplantation may be influenced by the local delivery matrix. A hydrogel or other biomaterial may provide physical support, retention at a target site, protection from mechanical disruption, and presentation of extracellular signals. Where the biomaterial presents a ligand that activates an artificial receptor expressed by the transplanted cells, the biomaterial may also provide spatial or temporal control over transgene expression. Such a configuration may be used to coordinate local anti-inflammatory activity, fate stabilization, maturation support, or other programmed cell responses during a post-transplant period relevant to engraftment and functional maturation.
[0053] Accordingly, Parkinson’s disease provides a principal therapeutic context for engineered midbrain dopaminergic progenitor cells described herein. The disease involves loss or dysfunction of dopaminergic neurons, impaired dopamine signaling, and progressive motor and non-motor deficits. A cell product capable of surviving the transplantation environment, responding to inflammatory stress, producing therapeutic antagonists of inflammatory mediators, and maintaining or promoting midbrain dopaminergic lineage identity may provide advantages over unmodified transplanted cells. Such cells may be used alone or in association with an implantable biomaterial to support survival, maturation, and functional persistence of dopaminergic lineage cells after delivery to a subject.III. Engineered iPSC-Derived mDA Progenitor CellsA. KOLF2.1J iPSCs
[0054] KOLF2.1J induced pluripotent stem cells are human induced pluripotent stem cells that may be used as a source cell population for producing midbrain dopaminergic (mDA) progenitor cells. The KOLF2.1J cell line provides a human pluripotent cellular substrate that can be expanded in culture, genetically engineered, differentiated toward an mDA lineage, and evaluated for receptor activation, transgene expression, maturation, and fate-stabilization. Because the cells are pluripotent and amenable to genetic modification, KOLF2.1J cells are144921-5119-9043, v. 2useful for generating engineered mDA progenitor cells having programmable responses to inflammatory cues, biomaterial-associated cues, or both.
[0055] KOLF2.1J cells are one non-limiting example of a source cell population suitable for generating engineered mDA progenitor cells. Other suitable source cell populations include, without limitation, other human induced pluripotent stem cell (iPSC) lines (including donor-derived iPSC lines and patient-derived iPSC lines), gene-edited iPSC lines, banked or clinical-grade iPSC lines, human embryonic stem cell (hESC) lines, and other human pluripotent stem cell (hPSC) lines capable of differentiation toward an mDA lineage. In some configurations, the source cell population comprises a neural stem cell, neural progenitor cell, or ventral midbrain-patterned progenitor cell population derived from a pluripotent stem cell source. In further configurations, the source cell population comprises a mixed population or a purified population enriched for cells committed to an mDA lineage, provided the population is compatible with introduction and / or expression of the genetic components described herein and is capable of producing cells having an mDA progenitor phenotype.
[0056] KOLF2.1J iPSCs may be maintained under conditions suitable for preserving pluripotency and supporting subsequent differentiation. For example, KOLF2.1J iPSCs may be cultured on an extracellular matrix-coated surface, such as a Geltrex-coated surface, in a pluripotent stem cell maintenance medium, such as StemFlex medium. The cells may be passaged or dissociated using reagents compatible with pluripotent stem cell culture, including ReLeSR or Accutase. These culture conditions provide a starting population that may be differentiated, engineered, or otherwise processed for preparation of the engineered cells described herein.
[0057] KOLF2.1J iPSCs may be differentiated toward an mDA progenitor state using culture conditions that promote neural induction, ventralization, and midbrain patterning. In certain configurations, the cells are exposed to a base mDA neuron medium comprising neurobasal medium, GlutaMax, N2 supplement, and B27 supplement without vitamin A, together with one or more agents that modulate developmental signaling pathways associated with mDA specification. Such agents may include, for example, LDN193189, SB431542, a Smoothened agonist, purmorphamine, Y-27632, CHIR99021, or combinations thereof. The differentiation conditions may include staged changes in media composition and signaling modulators to promote acquisition of an mDA progenitor phenotype. In some configurations,154921-5119-9043, v. 2the differentiation protocol includes a transition into Essential 6 medium, which may support formation of cells expressing one or more mDA progenitor markers.
[0058] KOLF2.1J-derived mDA progenitor cells may be identified or characterized by expression of markers associated with an mDA progenitor phenotype, including OTX2, FOXA2, LMX1A, EN1, or combinations thereof. The cells may be further cultured under maturation-supporting conditions, including in late mDA neuron medium containing one or more trophic or maturation-associated factors, such as brain-derived neurotrophic factor, glial cell line -derived neurotrophic factor, dibutyryl cyclic AMP, L-ascorbic acid, TGF-P3, CHIR99021, or combinations thereof. Maturation or lineage progression may be evaluated by expression of markers associated with mDA identity or function, including EN1, ALDH1A1, tyrosine hydroxylase, or other suitable markers.
[0059] KOLF2.1J iPSCs and KOLF2.1J-derived mDA progenitor cells may be engineered at one or more stages of cell preparation. Genetic engineering may be performed before differentiation, during differentiation, or after differentiation to an mDA progenitor state. Suitable engineering methods include viral transduction and non-viral gene delivery. For example, KOLF2.1J-derived mDA progenitor cells may be engineered by lentiviral transduction after differentiation. KOLF2.1J iPSCs may also be engineered using a transposase / transposon system, such as a Sleeping Beauty or piggyBac system, and thereafter differentiated into mDA progenitor cells while maintaining expression or inducibility of the introduced genetic components.
[0060] The genetic components introduced into KOLF2.1 J cells may include one or more artificial receptors, receptor-responsive expression cassettes, transgenes, reporter sequences, selectable markers, or combinations thereof. In some configurations, KOLF2.1J-derived mDA progenitor cells express a TNF-sensitive artificial receptor, such as a TNF-sensitive synthetic Notch receptor or a TNF-sensitive synthetic intramembrane proteolysis receptor (SNIPR). Such receptors may be configured to activate expression of a reporter transgene, a therapeutic transgene, a fate-stabilizing transgene, or a combination thereof in response to TNF.
[0061] KOLF2.1J cells may also be used to prepare cells responsive to orthogonal or biomaterial-associated cues. For example, KOLF2.1J iPSCs may be engineered to express a GFP -responsive artificial receptor, including a receptor comprising a GFP-binding domain 164921-5119-9043, v. 2such as LaG16. Such cells may be used to assess activation by soluble multimeric GFP-derived ligands, hydrogel-associated GFP ligands, or GFP-conjugated hydrogel materials. In this manner, KOLF2.1J cells provide a useful platform for evaluating how extracellular cues, including inflammatory cytokines and hydrogel-presented ligands, can be coupled to programmable transgene expression in human pluripotent stem cell-derived mDA lineage cells.
[0062] KOLF2.1J cells may further be used to evaluate transgenes that promote or stabilize mDA fate. For example, KOLF2.1J cells may be engineered to inducibly express transcription factors or signaling molecules associated with mDA specification or maturation, including NURR1, SOX6, WNT1, WNT3A, or another WNT ligand. Expression of such transgenes may be evaluated during differentiation or maturation by measuring mDA-associated markers, dopaminergic markers, or markers associated with particular dopaminergic neuronal states. In this regard, KOLF2.1J cells provide a human iPSC-derived system for assessing transgene-regulated maturation and fate stabilization of mDA progenitor cells.
[0063] Accordingly, KOLF2.1J iPSCs may be used as a reproducible human pluripotent source for generating engineered mDA progenitor cells. The cells may be used to produce TNF-responsive mDA progenitors, hydrogel ligand-responsive mDA progenitors, cells expressing therapeutic anti-inflammatory payloads, cells expressing fate-stabilizing pay loads, or cell populations combining two or more of these features. The resulting KOLF2.1 J-derived engineered mDA progenitor cells may be used for in vitro characterization, receptor optimization, transgene evaluation, biomaterial-response testing, preparation of implantable cell compositions, or transplantation-oriented studies.B. mDA precursor neurons
[0064] As used herein, “mDA precursor neuron,” “midbrain dopaminergic precursor neuron,” “mDA progenitor cell,” and related terms refer to a neural lineage cell that is committed to, differentiating toward, or capable of further maturation into a midbrain dopaminergic neuronal cell. Such cells may represent a developmental stage between a pluripotent stem cell or neural progenitor cell and a mature dopamine -producing neuron of the midbrain. An mDA precursor neuron may retain proliferative, migratory, maturation, engraftment, or lineage-plastic characteristics associated with a progenitor or precursor state, while also expressing one or more markers indicative of specification toward a midbrain dopaminergic lineage.174921-5119-9043, v. 2
[0065] mDA precursor neurons may be derived from pluripotent stem cells, including induced pluripotent stem cells, by exposure to culture conditions that promote neural induction, ventralization, midbrain patterning, and dopaminergic lineage specification. Such cells may be characterized by expression of one or more markers associated with midbrain or dopaminergic progenitor identity. Non-limiting examples of such markers include OTX2, FOXA2, LMX1A, and EN 1. These markers may be evaluated individually or in combination and may be detected by immunocytochemistry, qRT-PCR, fluorescence microscopy, flow cytometry, transcriptomic analysis, or another suitable assay. The expression profile of an mDA precursor neuron may vary according to the source cell, differentiation protocol, culture stage, maturation state, engineering method, or post-transplantation microenvironment.
[0066] mDA precursor neurons may continue to mature after formation from pluripotent stem cells or after delivery to a subject. During maturation, the cells may acquire one or more features associated with dopaminergic neuronal identity or function. Such features may include expression of tyrosine hydroxylase, expression of markers associated with an A9-like midbrain dopaminergic phenotype, expression of EN1 or ALDH1A1, reduced expression of markers associated with less desired dopaminergic states, development of neuronal morphology, neurite extension, responsiveness to trophic or differentiation cues, or production, handling, or release of dopamine or dopamine-associated pathway components. The precursor state may therefore provide a useful cellular stage for transplantation because the cell may be sufficiently specified toward an mDA lineage while retaining the capacity to mature, integrate, or adapt following delivery.
[0067] In normal physiology, mature midbrain dopaminergic neurons participate in neural circuits that regulate voluntary movement and other dopamine-dependent functions. A clinically important population of midbrain dopaminergic neurons is located in the substantia nigra pars compacta and projects to striatal circuitry. Dopamine released within such circuitry modulates activity of basal ganglia pathways involved in movement initiation, motor control, and motor coordination. Midbrain dopaminergic neurons may also participate in additional dopamine-associated functions, including motivation, reward, learning, and other central nervous system processes. Accordingly, precursor cells capable of maturing toward a midbrain dopaminergic phenotype are relevant to restoring or supporting dopaminergic signaling in conditions involving loss or dysfunction of such neurons.184921-5119-9043, v. 2
[0068] Parkinson’s disease is associated with degeneration or dysfunction of dopamine-producing neurons in the midbrain, including neurons of the substantia nigra pars compacta. Loss of these neurons reduces dopaminergic input to target regions such as the striatum and contributes to impaired motor control. Existing pharmacologic approaches may supplement or modulate dopaminergic signaling but do not replace the lost neuronal population. For this reason, human pluripotent stem cell-derived mDA precursor neurons have been investigated as a cellular source for transplantation-based approaches intended to provide cells capable of maturing into dopaminergic neurons and contributing to restoration of dopaminergic function.
[0069] mDA precursor neurons may be particularly suitable for transplantation because they can be generated in vitro, characterized before administration, genetically engineered before or after lineage specification, and delivered at a stage that supports continued maturation after implantation. The precursor state may provide advantages over a fully mature neuronal state by allowing the cells to tolerate handling, formulation, implantation, or association with a biomaterial, while retaining the capacity to further mature in response to local cues. Such precursor cells may also be engineered to express receptors, response elements, or transgenes before or after differentiation, thereby permitting preparation of cell populations having defined sensing and response properties.
[0070] The present disclosure contemplates mDA precursor neurons that are engineered to improve survival, maturation, functional persistence, or lineage stability after transplantation. In particular, mDA precursor neurons may be engineered to express an artificial receptor that senses an inflammatory signal, such as TNF, in a transplantation microenvironment. Activation of the receptor may induce expression of a transgene that reduces inflammatory injury, antagonizes TNF signaling, or otherwise supports survival of the mDA precursor neuron. Such a configuration is useful because transplanted mDA precursor neurons may encounter inflammatory cytokines, immune-mediated stress, mechanical stress, or other deleterious signals after implantation.
[0071] The present disclosure also contemplates mDA precursor neurons engineered to express a transgene that promotes or stabilizes mDA lineage identity. A fate-stabilizing factor may support maturation toward a desired midbrain dopaminergic state, maintain expression of mDA-associated markers, promote acquisition or maintenance of an A9-like phenotype,194921-5119-9043, v. 2enhance expression of dopaminergic functional markers, reduce drift away from the desired lineage state, or improve persistence of lineage- appropriate function after transplantation. Nonlimiting examples of fate-stabilizing factors include WNT ligands, NURR1, and SOX6. In some configurations, expression of a fate-stabilizing factor may be controlled by an artificial receptor responsive to a ligand presented by a biomaterial, thereby linking fate-supportive transgene expression to the local delivery environment.
[0072] An mDA precursor neuron may also be associated with a hydrogel, scaffold, matrix, or other biomaterial before, during, or after delivery. The biomaterial may support cell viability, retention, distribution, engraftment, maturation, or neurite extension. In some configurations, the biomaterial presents a ligand that activates an artificial receptor expressed by the mDA precursor neuron. Such ligand presentation may provide local control over transgene expression in cells associated with the biomaterial. For example, a hydrogel-integrated ligand may activate a receptor in the mDA precursor neuron to promote expression of a fate-stabilizing factor during a post-delivery period. As the biomaterial degrades, remodels, disperses, or otherwise changes, ligand presentation and receptor activation may decrease, thereby reducing expression of the corresponding transgene as the precursor cells mature.
[0073] mDA precursor neurons may be provided as a substantially homogeneous population or as a population enriched for cells having one or more desired lineage markers, receptor constructs, response cassettes, or maturation characteristics. The population may include cells at the same or different stages of mDA differentiation, including cells that express progenitor markers, cells undergoing maturation, and cells beginning to express markers associated with dopaminergic neuronal function. The population may be selected, sorted, enriched, expanded, matured, cryopreserved, formulated, or otherwise processed before use. The cells may be administered alone or in combination with a pharmaceutically acceptable carrier, hydrogel, granular hydrogel, hydrogel microparticles, scaffold, or other delivery material suitable for supporting cell viability and placement at a target site.
[0074] Accordingly, mDA precursor neurons serve as a cell population that bridges pluripotent stem cell-derived manufacturing and mature dopaminergic neuronal function. Within the present disclosure, such cells provide a substrate for programmable cell therapy because they may be generated from human iPSCs, specified toward a midbrain dopaminergic lineage, engineered to sense inflammatory or biomaterial-associated cues, and configured to204921-5119-9043, v. 2express therapeutic or fate-stabilizing transgenes. These properties make mDA precursor neurons useful for preparing cell compositions and implantable devices intended to enhance survival, reduce inflammatory injury, support maturation, and maintain midbrain dopaminergic lineage identity after delivery to a subject.
[0075] Engineered iPSC-derived mDA progenitor cells of the present disclosure include iPSC-derived cells that have been differentiated toward a midbrain dopaminergic lineage and modified to include one or more heterologous genetic components that confer a programmed sensing, response, therapeutic, survival-promoting, maturation-promoting, or fate-stabilizing function. Such cells may be derived from human induced pluripotent stem cells, including KOLF2.1J induced pluripotent stem cells, and may be engineered before, during, or after differentiation toward an mDA progenitor state. The engineered cells may retain one or more characteristics of an mDA progenitor cell after introduction of the heterologous genetic components and may remain capable of further maturation toward a dopaminergic neuronal phenotype.
[0076] The engineered iPSC-derived mDA progenitor cell may include one or more artificial receptors, one or more receptor-responsive expression cassettes, one or more transgenes, one or more reporter sequences, one or more selectable markers, or any combination thereof. The artificial receptor may be configured to bind a selected extracellular ligand and to activate expression of a transgene operably linked to a receptor-responsive regulatory element. The selected extracellular ligand may be an inflammatory mediator, a cytokine, a growth factor, a biomaterial-associated ligand, an orthogonal ligand, or another molecule present in or introduced into the local environment of the engineered cell. In certain configurations, the artificial receptor is responsive to tumor necrosis factor (TNF). In other configurations, the artificial receptor is responsive to a ligand integrated in a hydrogel or other biomaterial, such as green fluorescent protein (GFP), dimeric GFP, or a GFP -derived ligand.
[0077] The engineered iPSC-derived mDA progenitor cell may express an artificial TNF-sensitive receptor. The artificial TNF-sensitive receptor may include an extracellular TNF-binding domain and one or more receptor domains that permit ligand-dependent signaling or transcriptional activation. The extracellular TNF-binding domain may include a TNF-binding nanobody, single-domain antibody, single-chain variable fragment, antigen-binding fragment, antibody-derived binding domain, receptor-derived binding domain, or other TNF-214921-5119-9043, v. 2binding moiety. Non-limiting examples of TNF-binding domains include TNF3E and TNF-binding domains derived from anti-TNF agents, including ozoralizumab, certolizumab, adalimumab, or antigen-binding portions thereof.
[0078] The artificial receptor may be a regulated intramembrane proteolysis (RIP) receptor. RIP receptors suitable for use in the engineered iPSC-derived mDA progenitor cells include synthetic Notch receptors and synthetic intramembrane proteolysis receptors (SNIPRs). Such receptors may include an extracellular ligand-binding domain, one or more membrane-associated domains that support ligand-dependent receptor processing, and an intracellular domain that directly or indirectly regulates transcription of a receptor-responsive transgene. Upon ligand engagement, the receptor may undergo a conformational, proteolytic, or signaling event that results in transcriptional activation of an operably linked expression cassette. The modular nature of such receptors permits selection of the ligand-binding domain and the output transgene according to the desired cellular response.
[0079] The engineered iPSC-derived mDA progenitor cell may include a receptor-responsive expression cassette comprising a response element operably linked to a transgene. Activation of the artificial receptor may increase expression of the transgene relative to a condition in which the receptor is not activated. The transgene may encode a TNF antagonist, an anti-inflammatory factor, a survival-promoting factor, a fate-stabilizing factor, a maturationpromoting factor, a reporter, or a combination thereof. In certain configurations, the transgene encodes soluble TNF receptor 1 (sTNFRl), an anti-TNF binding domain, a WNT ligand, NURR1, SOX6, mCherry, firefly luciferase, or another desired output.
[0080] In certain configurations, the engineered iPSC-derived mDA progenitor cell is configured to sense TNF in a local inflammatory environment and express a TNF antagonist in response. Such a configuration permits the engineered cell to respond to a cytokine associated with transplantation-induced inflammation. The TNF antagonist may bind, sequester, neutralize, inhibit, or otherwise reduce TNF or TNF-mediated signaling. In addition to inducible transgene expression, an artificial TNF-sensitive receptor that includes a TNF-binding extracellular domain may reduce availability of TNF in the local environment by binding TNF at the cell surface. Accordingly, the engineered cell may provide receptor-mediated TNF binding, inducible expression of a TNF antagonist, or both.224921-5119-9043, v. 2
[0081] In other configurations, the engineered iPSC-derived mDA progenitor cell is configured to express a fate-stabilizing factor. A fate-stabilizing factor may promote, maintain, enhance, or stabilize one or more features of an mDA progenitor or mDA neuronal phenotype. Such a factor may support continued maturation, maintain expression of lineage-associated markers, increase expression of markers associated with a desired mDA state, reduce drift away from an mDA lineage state, enhance dopaminergic neuronal characteristics, or improve persistence of a desired cellular phenotype after transplantation. Non-limiting examples of fatestabilizing factors include WNT ligands, NURR1, SOX6, and functional variants or fragments thereof. WNT ligands may include WNT1, WNT3A, or another WNT family member suitable for supporting an mDA developmental program.
[0082] The engineered iPSC-derived mDA progenitor cell may also include an artificial receptor responsive to a ligand associated with a hydrogel or other biomaterial. The ligand may be conjugated to, immobilized on, embedded in, entrapped within, adsorbed to, or otherwise retained by the hydrogel or biomaterial. The receptor responsive to the hydrogel-associated ligand may include an extracellular binding domain that recognizes the ligand and an intracellular domain that activates a receptor-responsive expression cassette. In certain configurations, the ligand includes GFP, dimeric GFP, or a GFP -derived ligand, and the artificial receptor includes a GFP-binding agent, such as LaG16, LaG17, or another GFP-binding domain. Activation of such a receptor may be used to induce expression of a fatestabilizing factor while the engineered cell is associated with the hydrogel.
[0083] The engineered iPSC-derived mDA progenitor cell may include multiple artificial receptors or multiple receptor-responsive expression cassettes. For example, a first artificial receptor may be responsive to TNF and a second artificial receptor may be responsive to a hydrogel-associated ligand. The first receptor may regulate expression of a TNF antagonist, while the second receptor may regulate expression of a fate-stabilizing factor. Alternatively, a TNF-responsive receptor may regulate expression of a fate-stabilizing factor, a TNF antagonist, or both. The same engineered cell may therefore be configured to integrate inflammatory cues and biomaterial-associated cues and to produce one or more cellular outputs that support survival, inflammatory resistance, maturation, lineage stability, or functional persistence.
[0084] The engineered iPSC-derived mDA progenitor cells may be prepared as a population of cells. The population may include cells expressing the same or different artificial234921-5119-9043, v. 2receptors, cells comprising the same or different receptor-responsive expression cassettes, cells expressing the same or different transgenes, or cells at the same or different stages of mDA lineage maturation. The population may be enriched, selected, sorted, expanded, matured, cryopreserved, formulated, associated with a hydrogel, or otherwise processed before use. The engineered cell population may be used for in vitro characterization, receptor optimization, payload evaluation, biomaterial-response testing, preparation of implantable compositions, or delivery to a subject.C. mDA Progenitor Markers and Maturation Markers
[0085] The iPSC-derived mDA progenitor cells described herein may be characterized by expression of one or more markers associated with midbrain dopaminergic lineage specification, progenitor identity, maturation, or dopaminergic function. Marker expression may be assessed before engineering, after engineering, during maturation, after exposure to TNF, after activation of an artificial receptor, after expression of a transgene, or after association with a hydrogel or other biomaterial.
[0086] Markers associated with an mDA progenitor phenotype include, without limitation, OTX2, FOXA2, LMX1A, and EN1. OTX2 may be associated with midbrain identity, FOXA2 may be associated with ventral floor plate patterning, and LMX1 A and EN1 may be associated with midbrain dopaminergic lineage specification. The cells may be characterized by expression of one or more of these markers, and the presence, absence, or level of any single marker need not be determinative of cell identity when other lineage-associated characteristics are present.
[0087] The cells may also be evaluated for markers associated with maturation toward an mDA neuronal phenotype. Such markers include, without limitation, tyrosine hydroxylase, EN1, ALDH1A1, and other markers associated with dopaminergic neuronal identity or function. In some cases, ALDH1A1 may be used as a marker associated with an A9-like dopaminergic phenotype, and CALB1 may be evaluated as a marker associated with an alternate dopaminergic state. Marker profiles may be used to assess whether the cells are progressing toward, maintaining, or stabilizing a desired midbrain dopaminergic lineage state.
[0088] Marker expression may be assessed using immunocytochemistry, immunofluorescence microscopy, flow cytometry, fluorescence-activated cell sorting, qRT-244921-5119-9043, v. 2PCR, RNA sequencing, reporter expression, protein detection, image analysis, or another suitable assay. Such analyses may be performed qualitatively or quantitatively, including by determining marker presence, relative expression level, transcript abundance, protein abundance, fluorescence intensity, percentage of marker-positive cells, or cellular localization.
[0089] Marker analysis may be used to evaluate compatibility of genetic engineering with mDA lineage identity. For example, engineered iPSC-derived mDA progenitor cells may be assessed for retention of OTX2, FOXA2, LMX1A, EN1, or a combination thereof after introduction of an artificial receptor, receptor-responsive expression cassette, or transgene. Marker analysis may also be used to evaluate the effect of a fate-stabilizing factor, such as a WNT ligand, NURR1, or SOX6, on maturation or maintenance of an mDA lineage phenotype. In some cases, expression of a fate-stabilizing factor may be associated with increased or maintained expression of EN1, ALDH1 Al, tyrosine hydroxylase, or another marker indicative of mDA maturation or dopaminergic function.
[0090] The marker profiles described herein are not intended to impose a fixed or exclusive identity requirement. mDA progenitor and mDA neuronal differentiation proceeds through dynamic developmental states, and marker expression may vary according to source cell, culture condition, differentiation stage, engineering method, maturation state, analytical method, or post-delivery environment. Accordingly, the engineered iPSC-derived mDA progenitor cells may be identified by one or more lineage-associated markers in combination with the programmed receptor and transgene features described herein.D. Engineered Receptor / Payload Configurations
[0091] The engineered iPSC-derived mDA progenitor cells may comprise one or more receptor / payload systems configured to couple a selected extracellular input to a selected cellular output. The receptor / payload system may include an artificial receptor and a receptor-responsive expression cassette. The artificial receptor may bind a selected ligand, and the receptor-responsive expression cassette may comprise one or more response elements operably linked to a transgene encoding a therapeutic factor, TNF antagonist, fate-stabilizing factor, maturation-promoting factor, reporter, selection marker, or other desired payload.
[0092] In some configurations, the receptor / payload system is TNF-responsive. The engineered cell may express an artificial TNF-sensitive receptor comprising a TNF-binding extracellular domain and intracellular components that regulate transgene expression after TNF 254921-5119-9043, v. 2engagement. The receptor may be a synthetic Notch receptor, a synthetic intramembrane proteolysis receptor (SNIPR), or another regulated intramembrane proteolysis (RIP) receptor. The payload may encode a TNF antagonist, including soluble TNF receptor 1 (sTNFRl), a soluble TNF-binding fragment, an anti-TNF binding domain, a TNF-binding antibody fragment, a TNF-binding nanobody, or another agent that reduces TNF or TNF-mediated signaling.
[0093] In some configurations, a TNF-responsive receptor regulates expression of a fate-stabilizing factor. Such configurations may be useful where TNF or TNF-associated inflammatory signaling affects survival, maturation, or lineage stability of transplanted mDA lineage cells. The fate-stabilizing factor may comprise a WNT ligand, NURR1, SOX6, or another factor that supports mDA progenitor identity, maturation, dopaminergic marker expression, or persistence of a desired mDA lineage state.
[0094] In some configurations, the receptor / payload system is responsive to a ligand integrated in a hydrogel or other biomaterial. The ligand may be conjugated to, immobilized on, embedded in, entrapped within, adsorbed to, or otherwise retained by the hydrogel. The receptor may comprise an extracellular domain that binds the integrated ligand and an intracellular domain that activates expression of a payload. In certain configurations, the ligand comprises GFP, dimeric GFP, or a GFP-derived ligand, and the receptor comprises a GFP-binding agent, including LaG16, LaG17, or another GFP -binding domain. The payload may encode a fate-stabilizing factor, such as a WNT ligand, NURR1, SOX6, or another maturationsupporting or lineage-stabilizing factor.
[0095] Hydrogel ligand-responsive configurations may provide localized activation of transgene expression while the engineered cells are associated with the hydrogel. As the hydrogel degrades, remodels, disperses, or otherwise reduces ligand presentation, activation of the corresponding artificial receptor may decrease. Such configurations may coordinate expression of a fate-stabilizing payload with a period of engraftment, maturation, or adaptation after delivery.
[0096] The engineered cells may comprise more than one receptor / payload system. For example, a first artificial receptor may be responsive to TNF and regulate expression of a TNF antagonist, while a second artificial receptor may be responsive to a hydrogel-integrated ligand and regulate expression of a fate-stabilizing factor. Alternatively, a single receptor may 264921-5119-9043, v. 2regulate more than one payload, or multiple expression cassettes may independently regulate different pay loads in the same cell.
[0097] Reporter payloads may be included to evaluate receptor activity, engineering efficiency, differentiation compatibility, or responsiveness to a selected ligand. Non-limiting reporter payloads include fluorescent or luminescent proteins, such as mCherry, BFP, and firefly luciferase. Reporter payloads may be used during development, optimization, manufacturing, or characterization, and may be omitted or replaced by therapeutic or fatestabilizing payloads in a cell population intended for administration.
[0098] The receptor and payload components may be introduced into iPSCs, iPSC-derived mDA progenitor cells, or differentiating mDA lineage cells using viral or non-viral engineering methods. Suitable methods include lentiviral transduction, Sleeping Beauty transposase / transposon systems, piggyBac transposase / transposon systems, plasmid transfection, targeted integration, genome editing, episomal expression, or other approaches suitable for introducing heterologous genetic components into human pluripotent stem cell-derived cells. The receptor and payload components may be introduced before differentiation, during differentiation, or after differentiation to an mDA progenitor state.
[0099] The receptor / payload configuration may be selected to support one or more desired properties of the engineered iPSC-derived mDA progenitor cell, including viability, retention of mDA progenitor markers, responsiveness to TNF, responsiveness to a hydrogel-integrated ligand, inducible payload expression, reduced inflammatory marker expression, enhanced dopaminergic marker expression, maturation toward an mDA phenotype, or persistence of a desired lineage state.IV. Artificial Receptor SystemsA. Regulated Intramembrane Proteolysis (RIP) Receptors
[0100] A RIP receptor may be modular in structure. The extracellular ligandbinding domain may be selected to bind a desired input ligand, while the intracellular domain may be selected to regulate a desired output transgene. In this manner, a RIP receptor may couple a selected extracellular cue to expression of a selected therapeutic, anti-inflammatory, survival-promoting, maturation-promoting, fate-stabilizing, reporter, or selection payload. The input ligand may be a soluble ligand, multimeric ligand, immobilized ligand, biomaterial-274921-5119-9043, v. 2associated ligand, inflammatory mediator, cytokine, growth factor, orthogonal ligand, or another ligand present in or introduced into the local environment of the engineered cell.
[0101] Suitable extracellular ligand-binding domains include, without limitation, antibody-derived binding domains, antigen-binding fragments, single-chain variable fragments, single-domain antibodies, nanobodies, receptor-derived binding domains, ligand-binding proteins, engineered binding proteins, and functional variants thereof. The ligand-binding domain may recognize a naturally occurring ligand, such as TNF, TGF-pi, VEGF, or another biological factor, or may recognize an orthogonal or biomaterial-presented ligand, such as GFP, dimeric GFP, a GFP -derived ligand, fluorescein, or another ligand selected to activate the receptor in a defined local environment.
[0102] The intracellular domain of a RIP receptor may comprise a transcriptional regulator, transcription factor, transcriptional activator, DNA-binding domain, activation domain, or other regulatory domain capable of promoting expression of a transgene operably linked to a corresponding response element. The receptor-responsive expression cassette may comprise one or more response elements operably linked to a coding sequence for a payload. The payload may include a TNF antagonist, anti-inflammatory factor, fatestabilizing factor, maturation-promoting factor, reporter, selectable marker, or other desired gene product. The receptor and expression cassette may be encoded on the same nucleic acid construct or on different nucleic acid constructs.
[0103] RIP receptor systems suitable for the present disclosure include synthetic Notch receptors and synthetic intramembrane proteolysis receptors. Such receptors are particularly useful because the ligand-binding and transcriptional-output components may be independently selected to create cell programs responsive to disease-associated or biomaterial-associated cues. In the context of engineered iPSC-derived mDA progenitor cells, RIP receptors may be used to sense TNF in an inflammatory transplantation microenvironment, to sense a ligand integrated in a hydrogel or other biomaterial, or to coordinate multiple cell outputs that support survival, inflammation resistance, maturation, or lineage stability.B. synNotch Receptors
[0104] A synthetic Notch receptor, or synNotch receptor, is a synthetic receptor based on the regulated intramembrane proteolysis behavior of Notch-type signaling systems. A synNotch receptor may comprise an extracellular ligand-binding domain, a Notch-derived 284921-5119-9043, v. 2or Notch-like regulatory core that supports ligand-dependent receptor processing, and an intracellular transcriptional regulatory domain. Following engagement of a cognate ligand by the extracellular domain, the receptor may undergo cleavage or another activation event that releases or activates the intracellular domain. The intracellular domain may then regulate expression of a transgene operably linked to a response element recognized by the transcriptional regulatory domain.
[0105] The synNotch receptor may be configured by selecting an extracellular domain that binds a ligand of interest. Suitable extracellular domains include binding domains that recognize inflammatory mediators, cytokines, growth factors, cell-surface molecules, biomaterial-associated ligands, or orthogonal ligands. In certain configurations, a synNotch receptor comprises an extracellular domain that binds TNF. In other configurations, a synNotch receptor comprises an extracellular domain that binds GFP, dimeric GFP, or a GFP-derived ligand. A GFP-responsive synNotch receptor may comprise a GFP -binding agent, including LaG16, LaG17, or another GFP -binding domain.
[0106] A synNotch receptor may be used to regulate expression of any suitable payload. For example, the receptor may induce expression of a reporter payload, such as mCherry, BFP, or firefly luciferase, to evaluate receptor activation, engineering efficiency, or responsiveness to ligand. The receptor may also induce expression of a therapeutic or fatestabilizing payload, including a TNF antagonist, WNT ligand, NURR1, SOX6, or another transgene selected to support survival, inflammation resistance, maturation, or mDA lineage stability.
[0107] The synNotch receptor may be responsive to soluble, multimeric, immobilized, or biomaterial-associated ligands depending on the identity and presentation of the ligand. In certain configurations, multimeric ligands may activate synNotch signaling without separate material-mediated capture. In other configurations, ligand presentation by a hydrogel or other biomaterial may promote receptor activation by providing local immobilization, multivalent presentation, or sustained ligand availability. The receptor may therefore be configured for activation by a disease-associated soluble cue, a hydrogel-integrated cue, or an engineered ligand supplied to the local environment of the cell.
[0108] In the engineered iPSC-derived mDA progenitor cells described herein, synNotch receptors may be used to link extracellular sensing to inducible expression of 294921-5119-9043, v. 2transgenes that support the intended cellular function. A TNF-sensitive synNotch receptor may be used to induce expression of an anti-inflammatory payload or fate-stabilizing payload in response to TNF. A GFP-sensitive synNotch receptor may be used to induce expression of a fate-stabilizing payload when the engineered cell is associated with a GFP-functionalized hydrogel. Such configurations permit programmable regulation of cell outputs in response to local inflammatory signals or biomaterial-presented signals.C. SNIPR Receptors
[0109] A synthetic intramembrane proteolysis receptor, or SNIPR, is a synthetic RIP receptor that may comprise modular extracellular and intracellular domains and receptor components selected to support ligand-dependent transcriptional regulation. A SNIPR may comprise an extracellular ligand-binding domain that recognizes a selected ligand and intracellular components that regulate expression of a transgene upon receptor activation. The SNIPR architecture may be configured to provide robust expression, receptor processing, ligand responsiveness, or transcriptional output in mammalian cells, including stem cells, iPSC-derived cells, mDA progenitor cells, or other cells useful in cell therapy.
[0110] The extracellular domain of a SNIPR may comprise any suitable ligandbinding moiety. In certain configurations, the extracellular domain comprises a TNF-binding domain. The TNF-binding domain may comprise TNF3E, an anti-TNF antibody-derived binding domain, a TNF-binding nanobody, a TNF-binding single-chain variable fragment, or another TNF-binding moiety. Non-limiting examples of anti-TNF binding domains include domains derived from ozoralizumab, certolizumab, adalimumab, or antigen-binding portions thereof. The ligand-binding domain may be selected based on binding affinity, ligand specificity, receptor activation level, expression characteristics, manufacturability, or performance in the engineered cell type.
[0111] A SNIPR may regulate expression of a receptor-responsive transgene. In certain configurations, a TNF-sensitive SNIPR induces expression of a reporter payload, including mCherry or firefly luciferase, in response to TNF. In other configurations, the TNF-sensitive SNIPR induces expression of a therapeutic payload, including soluble TNF receptor 1 (sTNFRl), an anti-TNF binding domain, or another TNF antagonist. In further configurations, the SNIPR may induce expression of a fate-stabilizing payload, including a304921-5119-9043, v. 2WNT ligand, NURR1, S0X6, or another factor that supports mDA lineage identity or maturation.
[0112] A TNF-sensitive SNIPR may also contribute to TNF attenuation through ligand binding at the cell surface. Binding of TNF by the extracellular TNF-binding domain may reduce availability of TNF in the local environment, even apart from expression of a downstream therapeutic payload. When combined with inducible expression of a TNF antagonist, the SNIPR system may provide both receptor-mediated TNF binding and transgene-mediated TNF antagonism. Such configurations are useful for engineered mDA progenitor cells exposed to inflammatory conditions associated with transplantation.
[0113] The SNIPR may be introduced into an iPSC, differentiating iPSC-derived lineage cell, or iPSC-derived mDA progenitor cell using viral or non-viral genetic engineering methods. Suitable methods include lentiviral transduction and transposase / transposon systems, including piggyBac or Sleeping Beauty systems. The SNIPR may be encoded by a construct comprising a promoter operably linked to the receptor coding sequence. The corresponding payload may be encoded by a receptor-responsive expression cassette, including a response element operably linked to a reporter, therapeutic factor, or fatestabilizing factor. The receptor and payload may be introduced before differentiation, during differentiation, or after differentiation to an mDA progenitor state.D. TNF-Sensitive Receptors
[0114] A TNF-sensitive receptor is an artificial receptor configured to bind TNF and produce a cellular response following TNF engagement. The TNF-sensitive receptor may comprise an extracellular TNF-binding domain and one or more intracellular or membrane-associated domains that permit receptor activation and downstream transgene expression. The TNF-sensitive receptor may be a RIP receptor, including a synNotch receptor or a SNIPR. The receptor may be expressed by an engineered iPSC-derived mDA progenitor cell to permit the cell to sense TNF in a local inflammatory environment.
[0115] The extracellular TNF-binding domain may comprise any suitable TNF-binding moiety. Non-limiting examples include TNF3E, TNF-binding nanobodies, TNF-binding single-chain variable fragments, TNF-binding antibody fragments, TNF receptor-derived binding domains, and TNF-binding domains derived from anti-TNF agents. Anti-TNF-derived binding domains may include domains derived from ozoralizumab, certolizumab,314921-5119-9043, v. 2adalimumab, or other TNF-binding antibodies or antibody fragments. The TNF-binding domain may be selected to support ligand binding, receptor activation, receptor expression, and compatibility with the engineered mDA progenitor cell.
[0116] Upon TNF engagement, the TNF-sensitive receptor may activate expression of a receptor-responsive transgene. The transgene may encode a TNF antagonist, anti-inflammatory factor, fate-stabilizing factor, reporter, or other desired payload. In certain configurations, activation of the TNF-sensitive receptor induces expression of sTNFRl. In other configurations, activation induces expression of an anti-TNF binding domain or another TNF antagonist. In further configurations, activation induces expression of a fate-stabilizing factor, such as a WNT ligand, NURR1 , SOX6, or another factor that supports mDA maturation or lineage stability.
[0117] A TNF-sensitive receptor may be used to program a cell response to inflammation encountered after transplantation. TNF may be present in a post-delivery microenvironment and may affect survival, maturation, or lineage stability of transplanted mDA lineage cells. By coupling TNF sensing to expression of an anti-inflammatory or fatestabilizing payload, the engineered cell may produce a response preferentially when exposed to an inflammatory cue. This provides local, cue-responsive regulation of the payload, rather than constitutive expression in the absence of the relevant signal.
[0118] The TNF-sensitive receptor may also bind and sequester TNF through the extracellular TNF-binding domain. In certain configurations, receptor-mediated binding of TNF reduces TNF availability or attenuates TNF-associated inflammatory signaling independent of payload expression. In other configurations, receptor-mediated TNF binding is combined with inducible expression of a TNF antagonist. The engineered cell may therefore attenuate TNF-mediated inflammatory signaling through one or more mechanisms, including cell-surface TNF binding, transgene expression, or both.E. Hydrogel Ligand-Responsive Receptors
[0119] The engineered iPSC-derived mDA progenitor cells may comprise an artificial receptor responsive to a ligand integrated in a hydrogel or other biomaterial. The ligand may be conjugated to, immobilized on, embedded in, entrapped within, adsorbed to, or otherwise retained by the hydrogel. A hydrogel ligand-responsive receptor may comprise an324921-5119-9043, v. 2extracellular ligand-binding domain that recognizes the integrated ligand and an intracellular domain that activates expression of a receptor-responsive transgene upon ligand engagement.
[0120] In certain configurations, the hydrogel-integrated ligand comprises GFP, dimeric GFP, enhanced GFP, mutant GFP, superfolder GFP, a GFP-derived ligand, or a functional variant thereof capable of binding a GFP-binding agent. The receptor may comprise a GFP-binding extracellular domain, including LaG16, LaG17, or another GFP-binding agent. The receptor may be a synNotch receptor, SNIPR, or another RIP receptor configured to activate transgene expression upon engagement with the hydrogel-integrated ligand.
[0121] The hydrogel ligand-responsive receptor may regulate expression of a fate-stabilizing factor. For example, activation of a GFP-responsive receptor by GFP presented by a hydrogel may induce expression of a WNT ligand, NURR1, SOX6, or another factor that supports mDA progenitor identity, maturation, dopaminergic marker expression, or persistence of a desired mDA lineage state. The receptor may also regulate expression of a reporter payload during development or characterization of the system, including mCherry, BFP, firefly luciferase, or another detectable marker.
[0122] Hydrogel ligand-responsive receptor systems permit localized activation of transgene expression in cells positioned in proximity to the biomaterial. When an engineered cell is encapsulated within, seeded into, entrapped within, disposed on, or otherwise associated with a ligand-functionalized hydrogel, the receptor may be activated by ligand presentation from the hydrogel. Cells not associated with the ligand-functionalized hydrogel, or cells no longer exposed to sufficient ligand presentation, may exhibit reduced activation of the corresponding receptor. This configuration can provide spatial control over expression of a transgene in relation to the cell-delivery material.
[0123] Hydrogel ligand-responsive receptor systems may also provide temporal control. A hydrogel may degrade, remodel, disperse, or otherwise change after delivery. As ligand presentation decreases, activation of the receptor responsive to the hydrogel-integrated ligand may also decrease. This property may be used to coordinate expression of a fatestabilizing or maturation-promoting payload with a period during which transplanted cells are adapting, maturing, or engrafting. In this way, the hydrogel may serve as both a physical support for the cells and a local regulator of programmed gene expression.334921-5119-9043, v. 2F. Multi-Receptor Configurations
[0124] The engineered iPSC-derived mDA progenitor cells may comprise more than one artificial receptor. A multi-receptor configuration may allow a single engineered cell to respond to multiple extracellular cues and to produce one or more selected outputs. The cues may include inflammatory ligands, disease-associated ligands, biomaterial-associated ligands, orthogonal ligands, soluble ligands, immobilized ligands, or combinations thereof. The receptors may be of the same receptor class or of different receptor classes, including combinations of synNotch receptors, SNTPRs, other RIP receptors, or other artificial receptor systems.
[0125] In certain configurations, an engineered iPSC-derived mDA progenitor cell comprises a first artificial receptor responsive to TNF and a second artificial receptor responsive to a ligand integrated in a hydrogel. The first receptor may comprise a TNF-binding extracellular domain and may regulate expression of a TNF antagonist, such as sTNFRl or another anti-TNF payload. The second receptor may comprise an extracellular domain that binds a hydrogel-integrated ligand, such as GFP, dimeric GFP, or a GFP-derived ligand, and may regulate expression of a fate-stabilizing factor, such as a WNT ligand, NURR1, or SOX6.
[0126] In another configuration, a TNF-responsive receptor and a hydrogel ligand-responsive receptor may regulate different payloads that cooperate to improve cell survival, reduce inflammatory injury, support maturation, or stabilize mDA lineage identity. For example, TNF sensing may induce an anti-inflammatory response, while hydrogel ligand sensing may induce a maturation-supporting response. Alternatively, TNF sensing may induce a fate-stabilizing factor, and hydrogel ligand sensing may induce a second fate-stabilizing factor, reporter, or therapeutic payload. The receptor / payload arrangement may be selected according to the desired input-output logic for the engineered cell.
[0127] The receptors in a multi-receptor configuration may regulate separate expression cassettes or may converge on the same expression cassette. Separate cassettes may permit independent regulation of different pay loads by different extracellular signals. Convergent arrangements may permit more than one receptor to regulate the same payload or related payloads. The engineered cell may therefore be designed to produce a response to a single cue, to multiple independent cues, or to coordinated presentation of cues associated with inflammation and the delivery biomaterial.344921-5119-9043, v. 2
[0128] A multi-receptor configuration may also include one or more reporter payloads to facilitate receptor development, optimization, manufacturing, or quality control. A reporter may be used to assess activation of a TNF-responsive receptor, a hydrogel ligand-responsive receptor, or both. In a therapeutic cell product, a reporter may be omitted or replaced with a therapeutic, anti-inflammatory, fate-stabilizing, or maturation-promoting payload. The receptor configuration may be selected to preserve compatibility with iPSC culture, mDA differentiation, mDA progenitor marker expression, maturation capacity, and post-delivery cell function.
[0129] The use of more than one artificial receptor provides a modular framework for programming engineered iPSC-derived mDA progenitor cells to respond to the conditions encountered during transplantation and maturation. The cells may thereby sense an inflammatory mediator such as TNF, sense a hydrogel-integrated ligand presented by a biomaterial, or sense both signals. The resulting outputs may include TNF antagonism, reduced inflammatory signaling, expression of a fate-stabilizing factor, enhanced maturation, reporter expression, or combinations thereof. Such multi -receptor configurations provide flexibility for coordinating local inflammatory control with biomaterial-directed support of mDA progenitor survival and maturation.V. TNF-Responsive Anti-Inflammatory ProgramsA. TNF Sensing
[0130] Tumor necrosis factor (TNF) is a pro-inflammatory cytokine associated with inflammatory signaling in a transplantation microenvironment. In the context of midbrain dopaminergic lineage cell transplantation, TNF is particularly relevant because inflammatory signaling can reduce survival of transplanted dopamine lineage cells and may interfere with the ability of such cells to persist and mature after delivery. mDA precursor neurons and mDA progenitor cells may encounter TNF following implantation into central nervous system tissue as part of a local injury, immune, or inflammatory response.
[0131] TNF signaling may proceed through endogenous TNF receptors expressed by cells in the graft or surrounding tissue and may activate intracellular inflammatory pathways, including NF-KB-associated signaling. Activation of NF-KB signaling can induce inflammatory mediators and stress-response programs. In hPSC-derived dopamine lineage cells, TNF-associated inflammatory signaling has been implicated in reduced survival after354921-5119-9043, v. 2transplantation, including through a TNF / NF-i B / p53-associated cell death pathway. Thus, TNF provides both a marker of an inflammatory graft environment and a biologically relevant signal that may contribute to loss or impaired function of transplanted mDA lineage cells.
[0132] The engineered iPSC-derived mDA progenitor cells described herein may be configured to detect TNF as an extracellular indicator of inflammatory stress and to initiate a localized counter-regulatory response. In certain configurations, TNF detection is mediated by an artificial TNF-sensitive receptor that binds TNF and activates a receptor-responsive expression cassette. Activation of the cassette may induce expression of a TNF antagonist, such as soluble TNF receptor 1 (sTNFRl), an anti-TNF binding domain, or another payload capable of reducing TNF availability or TNF-mediated signaling.
[0133] TNF sensing may also be used to induce expression of a payload that supports mDA lineage stability or maturation. TNF-associated inflammation may affect not only cell survival but also the developmental trajectory or functional maturation of transplanted mDA precursor cells. Accordingly, activation of a TNF-responsive program may induce expression of a fate-stabilizing factor, such as a WNT ligand, NURR1, SOX6, or another factor that supports maintenance or maturation of an mDA phenotype.
[0134] The biological effect of TNF sensing may be evaluated by measuring receptor activation, payload expression, inflammatory pathway activity, inflammatory marker expression, cell survival, or mDA lineage marker expression following TNF exposure. For example, receptor activation may be assessed using a reporter payload, such as a fluorescent or luminescent reporter. Anti-inflammatory activity may be assessed by measuring reduced TNF pathway activity, reduced NF-KB -associated reporter activity, reduced expression of inflammatory markers such as CCL2, increased survival of engineered cells, or preservation of mDA progenitor or maturation markers after TNF exposure.
[0135] TNF sensing may therefore provide a mechanism by which engineered iPSC-derived mDA progenitor cells detect an inflammatory transplantation environment and respond in a manner that counteracts TNF-associated graft stress. The response may include receptor-mediated TNF binding, inducible expression of a TNF antagonist, inducible expression of a fate-stabilizing factor, or a combination thereof. Such TNF-responsive programs may support cell survival, reduce inflammatory signaling, and maintain a desired mDA lineage phenotype after delivery.364921-5119-9043, v. 2B. TNF-Binding Domains
[0136] TNF-binding domains useful in the present disclosure include binding moieties capable of recognizing TNF and thereby enabling TNF detection, TNF sequestration, TNF antagonism, or a combination thereof. Such domains may be used to position an engineered mDA progenitor cell to respond to a cytokine that is relevant to inflammatory stress in the graft microenvironment. In the context of transplanted mDA precursor neurons or mDA progenitor cells, TNF-binding domains provide a molecular interface between the inflammatory state of the tissue and a programmed cellular response intended to reduce inflammatory injury, improve survival, or support maturation.
[0137] In certain configurations, the TNF-binding domain comprises TNF3E. TNF3E may be used as a TNF-binding moiety that recognizes TNF with high affinity and can be incorporated into a TNF-responsive cellular program. When present on an engineered cell, TNF3E may bind TNF in the extracellular environment and thereby permit the cell to detect local TNF associated with inflammatory signaling. TNF3E may also contribute to local TNF attenuation by binding TNF at or near the engineered cell surface, reducing the amount of TNF available to engage endogenous TNF receptors on the engineered cell or neighboring cells.
[0138] TNF3E and other TNF-binding domains may be particularly useful where TNF-mediated inflammatory signaling affects survival or fate of transplanted dopamine-lineage cells. TNF engagement of endogenous TNF receptor pathways may activate NF-KB-associated signaling and downstream stress-response programs, including programs associated with p53-mediated cell death in hPSC-derived dopamine lineage cells. A TNF-binding domain positioned in an engineered cell program may therefore provide both a sensor of a biologically relevant inflammatory cue and a structural element that contributes to attenuation of the same cue.
[0139] Other TNF-binding domains may be derived from anti-TNF antibodies, antigen-binding fragments, single -chain variable fragments, single-domain antibodies, nanobodies, receptor-derived binding domains, or engineered binding proteins. Such domains may be selected based on TNF binding, specificity, expression, stability, compatibility with human iPSC-derived mDA progenitor cells, ability to support TNF-responsive signaling, or ability to reduce TNF-associated inflammatory activity. Non-limiting examples include TNF-374921-5119-9043, v. 2binding domains derived from ozoralizumab, certolizumab, adalimumab, or other TNF-binding agents.
[0140] A TNF-binding domain may be used as a sensing component, an effector component, or both. When used as a sensing component, the domain permits TNF in the local environment to initiate a programmed response. When used as an effector component, the domain may bind TNF after expression, secretion, or display and thereby reduce TNF availability or TNF-mediated signaling. A single engineered cell may therefore include a TNF-binding domain that detects TNF and a TNF-binding payload that antagonizes TNF, allowing the cell to integrate inflammatory sensing with local anti-inflammatory activity.C. TNF Antagonists
[0141] A TNF antagonist includes an agent that binds TNF, sequesters TNF, reduces TNF availability, inhibits TNF receptor engagement, decreases TNF-mediated signaling, or otherwise attenuates one or more biological activities associated with TNF. Within the present disclosure, TNF antagonists are useful because TNF may contribute to inflammatory signaling that compromises the survival, maturation, or functional persistence of transplanted mDA precursor neurons or mDA progenitor cells. A TNF antagonist expressed by an engineered mDA progenitor cell may reduce inflammatory stress in the local environment in which the cell is implanted or cultured.
[0142] TNF antagonism may act at one or more points in the TNF pathway. A TNF antagonist may bind soluble TNF before TNF engages endogenous TNF receptors, may reduce effective TNF concentration near the engineered cell, may decrease activation of NF-KB-associated signaling, may reduce expression of inflammatory mediators, or may reduce downstream stress-response activity associated with impaired survival. In mDA lineage cells, this is significant because TNF-associated signaling has been implicated in loss of hPSC-derived dopamine neurons after transplantation, including through NF-KB- and p53-associated pathways.
[0143] TNF antagonists suitable for expression by engineered iPSC-derived mDA progenitor cells include soluble receptor-derived molecules, antibody-derived binding molecules, single-domain binding molecules, nanobodies, single-chain variable fragments, antigen-binding fragments, and engineered TNF-binding proteins. Non-limiting examples include soluble TNF receptor 1 (sTNFRl), soluble TNF receptor fragments, anti-TNF binding 384921-5119-9043, v. 2domains, and TNF-binding domains derived from ozoralizumab, certolizumab, adalimumab, or other TNF-binding agents. Such antagonists may be secreted, displayed, retained extracellularly, or otherwise configured to reduce local TNF activity.
[0144] In certain configurations, expression of a TNF antagonist is induced by TNF exposure. In this arrangement, TNF functions as both the inflammatory stimulus and the cue that triggers expression of the antagonist. This creates a local counter-regulatory program in which engineered cells produce anti-inflammatory activity in response to the inflammatory signal being targeted. Such a program may avoid unnecessary constitutive expression while allowing increased antagonist production in environments where TNF signaling is present.
[0145] The effectiveness of a TNF antagonist may be evaluated by measuring TNF pathway activity, NF-KB-associated signaling, expression of inflammatory markers, cell viability, apoptosis-associated markers, or preservation of mDA progenitor or maturation markers after TNF exposure. In certain configurations, reduced expression of CCL2 or another inflammatory marker may indicate attenuation of TNF-associated inflammatory signaling. Increased survival or preserved marker expression may indicate that TNF antagonism supports the desired mDA lineage cell state.D. sTNFRl
[0146] Soluble TNF receptor 1 (sTNFRl) is a receptor-derived TNF antagonist suitable for use as an anti-inflammatory payload in engineered iPSC-derived mDA progenitor cells. sTNFRl may comprise a soluble form, fragment, variant, or functional portion of TNF receptor 1 capable of binding TNF. By binding TNF extracellularly, sTNFRl may reduce the availability of TNF to activate endogenous TNF receptors and thereby attenuate downstream inflammatory signaling.
[0147] sTNFRl is structurally related to the extracellular ligand-binding portion of TNF receptor 1. In soluble form, the TNF-binding portion may be released, secreted, or otherwise made available outside the engineered cell. The soluble configuration permits sTNFRl to interact with TNF in the local environment surrounding the engineered mDA progenitor cell. This local activity is useful in a transplantation microenvironment where TNF may be present as part of an inflammatory response to tissue injury or cell delivery.394921-5119-9043, v. 2
[0148] When expressed by an engineered iPSC-derived mDA progenitor cell, sTNFRl may function as a locally produced TNF sink. By binding TNF, sTNFRl may reduce TNF receptor engagement and decrease activation of downstream inflammatory pathways, including NF-KB -associated signaling. In the context of mDA precursor or progenitor cells, this may reduce cytokine-associated stress, reduce inflammatory gene expression, and support survival or continued maturation of the transplanted cell population.
[0149] sTNFRl may be expressed in a TNF-responsive manner. In such configurations, exposure of the engineered cell to TNF induces sTNFRl production, thereby coupling detection of an inflammatory cue to production of an antagonist directed against that cue. This feedback-responsive arrangement is well suited to transplantation-associated inflammation because the engineered cells may increase anti-TNF activity in response to the local presence of TNF.
[0150] Production or activity of sTNFRl may be assessed by detecting sTNFRl protein in cell culture medium or biological samples, measuring TNF binding or TNF neutralization, assessing downstream inflammatory pathway activity, or evaluating inflammatory marker expression. For example, reduced CCL2 expression after TNF exposure may indicate that sTNFRl production attenuates TNF-associated inflammatory signaling. sTNFRl activity may also be evaluated by measuring cell viability, preservation of mDA progenitor markers, maturation marker expression, or other readouts reflecting protection of engineered mDA lineage cells under inflammatory conditions.
[0151] The sTNFRl payload may include sequence features that support expression, secretion, stability, or detection. Such features may include a secretion signal, linker, stabilizing domain, multimerization domain, detection tag, purification tag, or other elements compatible with TNF binding and expression in iPSC-derived mDA progenitor cells. Such modifications may be selected to preserve TNF-binding activity while improving local availability or functional performance of the antagonist.E. Anti-TNF Domains, Including Ozoralizumab-Derived Domains
[0152] Anti-TNF domains provide another class of TNF-binding structures useful for TNF-responsive anti-inflammatory programs. Such domains may include antibody-derived binding domains, antigen-binding fragments, single-chain variable fragments, singledomain antibodies, nanobodies, complementarity-determining region-containing domains, or 404921-5119-9043, v. 2other engineered binding moieties that recognize TNF. These domains may be used to detect TNF, antagonize TNF, or provide both sensing and effector functions within an engineered mDA progenitor cell program.
[0153] Ozoralizumab-derived TNF-binding domains are one example of anti-TNF domains useful in the present disclosure. An ozoralizumab-derived domain may be adapted into a format suitable for expression by engineered iPSC-derived mDA progenitor cells. Such a domain may be used as a TNF-binding element in a TNF-responsive program or may be expressed as a soluble or otherwise available anti-TNF payload. The domain may be configured to bind TNF and reduce TNF availability in the local environment.
[0154] Anti-TNF domains are important because they provide structurally defined TNF-binding modules that can be incorporated into engineered cell programs. Unlike small molecules that broadly modulate downstream inflammation, anti-TNF binding domains directly target the cytokine input that contributes to inflammatory signaling. In mDA lineage cell transplantation, this permits localized intervention at the level of TNF itself, before or during activation of downstream NF-KB-associated stress pathways.
[0155] Anti-TNF domains derived from other TNF-binding agents may also be used. Non-limiting examples include domains derived from certolizumab, adalimumab, infliximab, golimumab, etanercept-derived TNF-binding portions, or other TNF-binding proteins. Such domains may differ in affinity, valency, format, size, stability, expression, secretion, or compatibility with a selected engineered cell system. The domain format may be selected to support TNF binding while maintaining expression and function in iPSC-derived mDA progenitor cells.
[0156] An anti-TNF domain may be engineered for receptor display, secretion, extracellular retention, multimerization, stabilization, or other functional properties. For example, an anti-TNF domain may be expressed as a single-chain construct, a single-domain construct, a fusion protein, a multivalent protein, or a soluble binding protein. Such structures may allow the engineered cell to produce a localized anti-TNF effect that reduces inflammatory signaling and supports mDA progenitor survival or maturation.
[0157] The activity of anti-TNF domains may be evaluated using assays that measure TNF binding, TNF-dependent pathway activation, NF-KB-associated reporter activity,414921-5119-9043, v. 2inflammatory marker expression, cell survival, or preservation of mDA lineage markers. In some cases, the anti-TNF domain may be compared to sTNFRl or another TNF antagonist to evaluate relative performance in reducing TNF-mediated stress or supporting engineered mDA progenitor cell function.F. TNF Neutralization Independent of Payload Expression
[0158] TNF-responsive anti-inflammatory programs may include TNF attenuation that occurs independently of expression of a downstream therapeutic payload. In such cases, a TNF-binding domain displayed by an engineered cell may bind TNF at or near the cell surface and thereby reduce the amount of TNF available to activate endogenous TNF receptors. This mechanism is distinct from secretion of a soluble antagonist, although both mechanisms may be present in the same engineered cell.
[0159] Payload-independent TNF attenuation may be particularly relevant where TNF is present immediately after transplantation or before a receptor-responsive pay load has accumulated to a therapeutic level. A cell-surface TNF-binding domain may provide an early local buffering effect by capturing TNF in the graft environment. Such binding may reduce TNF receptor engagement, reduce downstream NF-KB-associated signaling, and reduce inflammatory stress experienced by the engineered cell or neighboring cells.
[0160] This mechanism may also allow an engineered cell to provide antiinflammatory activity even when the downstream payload is not itself an anti-TNF agent. For example, a TNF-sensitive program may bind TNF through an extracellular TNF-binding domain while inducing expression of a fate-stabilizing payload, such as a WNT ligand, NURR1, SOX6, or another maturation-supporting factor. In that configuration, TNF binding may attenuate the inflammatory cue, while the induced payload supports mDA lineage maintenance or maturation.
[0161] Payload-independent TNF neutralization may also complement inducible expression of a TNF antagonist. A TNF-sensitive engineered cell may bind TNF at the cell surface and, upon activation, express sTNFRl or another TNF antagonist. Cell-surface TNF binding may reduce local TNF availability, while the expressed antagonist may provide additional soluble or extracellular TNF-binding capacity. The combined effect may produce a layered anti-inflammatory response to TNF exposure.424921-5119-9043, v. 2
[0162] The effect of payload-independent TNF attenuation may be assessed using inflammatory pathway readouts. For example, cells expressing a TNF-binding artificial receptor but lacking an anti-inflammatory payload may be compared with cells lacking the TNF-binding receptor under similar TNF exposure conditions. Reduced NF-KB-associated reporter activity, reduced inflammatory marker expression, reduced CCL2 expression, increased cell survival, or preservation of mDA lineage markers may indicate that TNF binding by the engineered cell contributes to attenuation of TNF-mediated signaling.
[0163] TNF neutralization independent of payload expression provides an additional mechanism by which engineered iPSC-derived mDA progenitor cells may resist inflammatory stress. This mechanism may operate alone or together with induced expression of sTNFRl, anti-TNF binding domains, fate-stabilizing factors, or other payloads. In the transplantation setting, such combined activities may improve survival, reduce inflammatory signaling, and support maintenance or maturation of the desired mDA lineage phenotype. VI. Fate-Stabilizing and Maturation-Promoting ProgramsA. Fate Stabilization
[0164] The engineered iPSC-derived mDA progenitor cells described herein may be configured to express one or more fate-stabilizing or maturation-promoting factors. A fate-stabilizing factor may include a protein, transcription factor, morphogen, signaling ligand, regulatory RNA, or other gene product that supports maintenance, maturation, or functional persistence of an mDA progenitor or mDA neuronal lineage cell. Such factors may promote midbrain identity, dopaminergic lineage specification, maturation toward a dopaminergic neuronal phenotype, maintenance of an A9-like state, expression of dopaminergic functional markers, survival, engraftment, or persistence after delivery.
[0165] Fate stabilization is useful because iPSC-derived mDA progenitor cells may be exposed after transplantation to inflammatory cytokines, altered trophic support, extracellular matrix changes, mechanical stress, immune activation, hypoxia, or other cues that affect survival or lineage progression. These conditions may reduce cell survival, alter maturation, or promote drift away from a desired mDA lineage state. Expression of a fatestabilizing factor may support the desired cellular identity during adaptation to the transplantation microenvironment.434921-5119-9043, v. 2
[0166] The fate-stabilizing factor may be expressed constitutively or inducibly, including in response to an inflammatory cue or to a ligand associated with a hydrogel or other biomaterial. In some configurations, expression of the fate-stabilizing factor is linked to the period during which the engineered cell is associated with a ligand-functionalized hydrogel, such that expression decreases as hydrogel degradation or remodeling reduces ligand presentation. In other configurations, expression is induced by TNF or another inflammatory signal, thereby coupling inflammatory stress to a lineage-supportive response.
[0167] Suitable fate-stabilizing factors include, without limitation, WNT ligands, NURR1, SOX6, and functional variants or fragments thereof. Such factors may be expressed individually or in combination to support mDA lineage maintenance, maturation, dopaminergic marker expression, or persistence of a desired mDA phenotype.B. WNT Ligands
[0168] WNT ligands are secreted signaling proteins involved in developmental pathways relevant to midbrain patterning, progenitor allocation, dopaminergic lineage specification, and neuronal maturation. In the engineered cells described herein, a WNT ligand may be used as a fate-stabilizing or maturation-promoting payload to support developmental signaling activities associated with an mDA lineage state.
[0169] WNT ligands may participate in canonical WNT / p-catenin-associated signaling. In this pathway, WNT ligand engagement of cell-surface receptors can stabilize P-catenin and promote P-catenin-dependent transcriptional regulation of downstream genes involved in cell fate, progenitor allocation, proliferation, and differentiation. In mDA lineage cells, WNT-associated signaling is relevant because ventral midbrain dopaminergic neuron development is influenced by WNT-regulated programs that control progenitor identity, dopaminergic commitment, and differentiation toward dopamine-producing neurons.
[0170] Expression of a WNT ligand by an engineered iPSC-derived mDA progenitor cell may reinforce signaling pathways associated with ventral midbrain identity, dopaminergic progenitor specification, or maturation toward a dopamine-producing neuronal phenotype. The WNT ligand may be expressed in response to a selected cue, including TNF or a hydrogel-associated ligand, to provide localized or temporally controlled WNT-associated signaling during a period of inflammatory stress, engraftment, or biomaterial-supported maturation.444921-5119-9043, v. 2
[0171] Suitable WNT ligands include WNT family members capable of supporting mDA progenitor maintenance, maturation, or dopaminergic lineage support. Nonlimiting examples include WNT1 and WNT3A. Additional WNT ligands, functional fragments, variants, or engineered derivatives may also be used where they retain activity relevant to mDA lineage support. A WNT ligand may be expressed alone or in combination with another fate-stabilizing factor, including NURR1 or SOX6.C. NURR1
[0172] NURR1, also known as NR4A2, is a nuclear receptor transcription factor associated with dopaminergic neuron development, maturation, and maintenance. NURR1 may be expressed as a fate-stabilizing or maturation-promoting payload in engineered iPSC-derived mDA progenitor cells to support a dopaminergic transcriptional program and maintain features of an mDA neuronal phenotype.
[0173] NURR1 may aid fate stabilization by reinforcing expression of genes associated with dopamine synthesis, transport, and vesicular handling. Such genes may include tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter 2, and aromatic L-amino acid decarboxylase. By supporting this dopaminergic functional gene program, NURR1 may help an mDA lineage cell acquire or maintain characteristics associated with dopamine-producing neurons.
[0174] A transgene encoding NURR1 may be expressed constitutively or under inducible control, including in response to TNF or a hydrogel-associated ligand. Inducible NURR1 expression may provide transcriptional support during maturation, engraftment, or inflammatory stress. NURR1 may be used alone or in combination with another fate-stabilizing factor, such as SOX6, WNT1, WNT3A, or another WNT ligand.
[0175] NURR1 activity may be evaluated by measuring mDA lineage or maturation markers, including EN1, ALDH1A1, tyrosine hydroxylase, or other markers associated with dopaminergic identity or function. Such analysis may be used to determine whether NURR1 supports maturation, dopaminergic functional marker expression, marker maintenance, or reduced drift away from a desired mDA lineage state.454921-5119-9043, v. 2D. SOX6
[0176] SOX6 is a transcription factor useful as a fate-stabilizing or maturationpromoting payload in engineered iPSC-derived mDA progenitor cells. SOX6 may support features associated with a desired mDA neuronal state, including features associated with substantia nigra-like or A9-like dopaminergic identity.
[0177] SOX6 may aid fate stabilization by promoting or maintaining transcriptional features associated with substantia nigra dopaminergic neuron specification. SOX6 has been associated with specification of substantia nigra dopamine neurons and with molecularly distinguishable dopaminergic neuron populations within the substantia nigra pars compacta. A SOX6-positive population in the ventral substantia nigra pars compacta has been described as including an ALDH1 Al -positive subset and as having distinct molecular, projection, and functional properties. Accordingly, SOX6 may support a dopaminergic subtype profile relevant to Parkinson’s disease-related cell replacement approaches.
[0178] A transgene encoding SOX6 may be expressed constitutively or under inducible control, including in response to TNF or a hydrogel-integrated ligand. SOX6 may be used alone or in combination with another fate-stabilizing factor, including NURR1, WNT1, WNT3 A, or another WNT ligand, to support maturation, dopaminergic marker expression, A9-like identity, or persistence of a desired mDA phenotype.
[0179] SOX6 expression may be evaluated using mDA fate and maturation readouts. In some configurations, SOX6 expression may be associated with increased or maintained expression of EN1, ALDH1A1, tyrosine hydroxylase, or a combination thereof. CALB 1 may be evaluated as a marker associated with an alternate dopaminergic state in certain contexts. The relative marker profile may be used to assess whether SOX6 supports a desired mDA lineage profile.VII. Hydrogel-Based Activation and Delivery
[0180] The engineered iPSC-derived mDA progenitor cells described herein may be provided in association with a hydrogel or other biomaterial suitable for delivery to a target tissue site. The hydrogel may support placement, retention, viability, maturation, neurite extension, engraftment, or localized activity of the engineered cells. The hydrogel may also present one or more ligands configured to activate an artificial receptor expressed by the464921-5119-9043, v. 2engineered cells, thereby functioning as both a delivery material and a local regulator of programmed cellular activity.
[0181] The engineered cells may be associated with the hydrogel in any suitable manner, including by being encapsulated within, seeded into, entrapped within, embedded in, suspended in, mixed with, disposed on, adhered to, or otherwise physically combined with the hydrogel. The hydrogel may maintain the engineered cells near the site of administration while permitting diffusion of nutrients, oxygen, cytokines, growth factors, secreted payloads, and other soluble molecules.
[0182] The hydrogel may comprise any suitable natural, synthetic, semisynthetic, or modified polymeric material. Suitable hydrogel materials include, without limitation, gelatin-based hydrogels, gelatin methacryloyl hydrogels, peptide-functionalized hydrogels, peptide-functionalized gelatin methacryloyl hydrogels, hyaluronic acid-based hydrogels, polyethylene glycol-based hydrogels, alginate-based hydrogels, collagen-based hydrogels, fibrin-based hydrogels, or combinations thereof. The hydrogel may include one or more cell-adhesive or cell-supportive features, including a peptide, protein, extracellular matrix component, or functional fragment thereof that supports cell attachment, viability, neurite extension, or maturation.
[0183] In some configurations, the hydrogel comprises a granular hydrogel comprising a plurality of hydrogel microparticles. The hydrogel microparticles may be formed from GelMA, peptide-functionalized GelMA, or another biocompatible hydrogel material. The microparticles may define an interstitial pore network into which the engineered iPSC-derived mDA progenitor cells are seeded, entrapped, suspended, or otherwise positioned. Such pore networks may support cell distribution, nutrient access, local retention, and exposure to hydrogel-presented ligands.
[0184] The hydrogel may comprise one or more ligands integrated in or associated with the hydrogel. A ligand may be conjugated to, immobilized on, embedded in, entrapped within, adsorbed to, covalently attached to, non-covalently associated with, or otherwise retained by the hydrogel. The ligand may activate an artificial receptor expressed by the engineered iPSC-derived mDA progenitor cells and thereby induce expression of a receptor-responsive transgene.474921-5119-9043, v. 2
[0185] In some configurations, the ligand comprises GFP, dimeric GFP, enhanced GFP, mutant GFP, superfolder GFP, a GFP-derived ligand, or a functional variant thereof capable of binding a GFP-binding agent. The engineered cells may express an artificial receptor comprising a GFP-binding domain, including LaG16, LaG17, or another GFP-binding agent. Activation of the receptor by the hydrogel-integrated ligand may induce expression of a fate-stabilizing factor, maturation-promoting factor, reporter, therapeutic factor, or other payload. Suitable fate-stabilizing factors include WNT ligands, WNT1, WNT3A, NURR1, SOX6, or other factors that support mDA progenitor identity, mDA maturation, dopaminergic marker expression, or persistence of a desired mDA lineage phenotype.
[0186] The degree of receptor activation may be tuned by altering ligand density, ligand valency, ligand distribution, ligand accessibility, hydrogel composition, microparticle size, microparticle packing, hydrogel stiffness, or the amount of ligand-functionalized material included in the composition. In some configurations, GFP or a GFP-derived ligand is conjugated to a GelMA hydrogel or to hydrogel microparticles to activate GFP -responsive engineered cells. Tunable ligand presentation may permit localized or temporally controlled expression of reporter, therapeutic, or fate-stabilizing payloads.
[0187] The hydrogel may be degradable. Hydrogel degradation may occur by hydrolysis, enzymatic cleavage, cellular remodeling, physical erosion, diffusion, dilution, disassembly, or another process that reduces hydrogel structure, ligand presentation, mechanical integrity, or local persistence. As the hydrogel degrades, remodels, disperses, or otherwise reduces presentation of the integrated ligand, activation of the corresponding artificial receptor may decrease, thereby reducing expression of the receptor-responsive transgene.
[0188] Timed reduction of receptor activation may be useful during maturation of engineered iPSC-derived mDA progenitor cells. Following delivery, the cells may benefit from hydrogel support, ligand presentation, and expression of fate-stabilizing factors during an initial period of engraftment, survival, adaptation, or maturation. As the cells mature and hydrogel ligand presentation decreases, expression of the corresponding payload may also decrease. The degradation profile of the hydrogel may be selected based on material composition, crosslinking density, polymer chemistry, microparticle size, peptide content,484921-5119-9043, v. 2enzymatically cleavable linkers, hydrogel architecture, ligand functionalization, or combinations thereof.
[0189] The hydrogel may be included in a cell composition, implantable composition, implantable device, or other formulation suitable for administration to a subject. In some configurations, the hydrogel-associated engineered iPSC-derived mDA progenitor cells are delivered to a central nervous system tissue site, including a site relevant to Parkinson’s disease cell replacement therapy. Hydrogel performance may be evaluated by measuring cell viability, cell retention, neurite extension, receptor activation, reporter expression, fate-stabilizing payload expression, ligand retention, hydrogel persistence or degradation, mDA progenitor marker expression, maturation marker expression, or other functional features of the engineered cells.VIII. Implantable Devices and CompositionsA. Cell-Hydrogel Compositions
[0190] present disclosure provides cell-hydrogel compositions comprising engineered iPSC-derived mDA progenitor cells associated with a hydrogel. The engineered cells may be encapsulated within, seeded into, entrapped within, embedded in, suspended in, mixed with, disposed on, adhered to, or otherwise physically combined with the hydrogel. The hydrogel may support local placement, retention, viability, maturation, neurite extension, engraftment, or localized activity of the engineered cells after administration.
[0191] The cell-hydrogel composition may comprise a bulk hydrogel, a granular hydrogel, hydrogel microparticles, or a combination thereof. In some configurations, the hydrogel comprises a granular hydrogel comprising a plurality of hydrogel microparticles that define an interstitial pore network. The engineered iPSC-derived mDA progenitor cells may be seeded into or entrapped within the interstitial pore network.
[0192] The hydrogel may comprise a ligand integrated in or associated with the hydrogel. In some configurations, the ligand comprises GFP, dimeric GFP, or a GFP-derived ligand and activates an artificial receptor expressed by the engineered cells. Activation of the artificial receptor may induce expression of a receptor-responsive transgene, including a fatestabilizing factor, maturation-promoting factor, reporter, therapeutic factor, or other payload.494921-5119-9043, v. 2
[0193] The cell-hydrogel composition may be formulated for administration to a target tissue site, including a central nervous system tissue site. The composition may be prepared as an injectable, implantable, moldable, flowable, pre-formed, in situ-forming, or otherwise administrable composition.B. Implantable Devices
[0194] The present disclosure also provides implantable devices comprising a plurality of engineered iPSC-derived mDA progenitor cells. The implantable device may comprise a hydrogel associated with the plurality of engineered cells. The hydrogel may serve as a structural, delivery, retention, or signaling component of the device.
[0195] In some configurations, the implantable device comprises a granular hydrogel comprising hydrogel microparticles. The engineered cells may be positioned within or among the hydrogel microparticles, including within an interstitial pore network formed by the microparticles. Such configurations may support three-dimensional distribution of cells, local retention after implantation, and exposure of the cells to hydrogel-associated cues.
[0196] The implantable device may include a ligand integrated in the hydrogel and configured to activate an artificial receptor expressed by the engineered cells. In some configurations, the ligand comprises GFP, dimeric GFP, or a GFP-derived ligand. Activation of the artificial receptor may induce expression of a fate-stabilizing factor, including a WNT ligand, WNT1, WNT3A, NURR1, SOX6, or another factor that supports mDA progenitor identity, maturation, or dopaminergic marker expression.
[0197] The implantable device may be configured so that hydrogel size, microparticle size, ligand density, ligand functionalization, degradation profile, cell density, cell distribution, or combinations thereof support viability of the engineered cells after implantation and activation of an artificial receptor expressed by the engineered cells.C. CNS-Compatible Delivery Formats
[0198] The cell-hydrogel compositions and implantable devices described herein may be configured for delivery to a central nervous system tissue site. In some configurations, the compositions or devices are used to deliver engineered iPSC-derived mDA progenitor cells to a site relevant to Parkinson’s disease cell replacement therapy.504921-5119-9043, v. 2
[0199] A CNS-compatible delivery format may comprise an injectable composition, implantable hydrogel composition, granular hydrogel composition, hydrogel microparticle composition, cell suspension combined with hydrogel material, pre-formed hydrogel implant, in situ-forming hydrogel, or other format suitable for placing the engineered cells at a target CNS site. The composition may be administered through a cannula, needle, catheter, stereotactic delivery device, surgical applicator, or other delivery instrument suitable for CNS administration.
[0200] The delivery format may be selected to permit flow during administration and retention after placement. For example, a granular hydrogel or hydrogel microparticle composition may be configured to permit delivery through an administration device while forming or maintaining a local cell-supportive material at the target site. The delivery format may also permit diffusion of oxygen, nutrients, cytokines, growth factors, receptor ligands, and secreted payloads.
[0201] In some configurations, the delivery format includes a degradable hydrogel. Degradation of the hydrogel may reduce ligand presentation and thereby reduce activation of a hydrogel ligand-responsive artificial receptor over time. Such timed reduction of receptor activation may be selected to correspond to maturation of the engineered iPSC-derived mDA progenitor cells.D. Viability, Engraftment, and Neurite Support
[0202] The implantable devices and cell-hydrogel compositions described herein may be configured to support viability, engraftment, neurite extension, maturation, or functional persistence of engineered iPSC-derived mDA progenitor cells after delivery. The hydrogel may reduce physical disruption during administration, support retention of the engineered cells at the target site, provide a hydrated three-dimensional environment, and facilitate exposure to cell-supportive or receptor-activating cues.
[0203] The hydrogel may include one or more features that promote cell viability or neurite support. Such features may include cell-adhesive peptides, extracellular matrix components, peptide-functionalized polymer components, degradable linkers, controlled stiffness, appropriate porosity, interstitial pore networks, or other structural or biochemical properties that support survival, cell attachment, neurite extension, maturation, or interaction with the local tissue environment.514921-5119-9043, v. 2
[0204] The compositions and devices may also support engraftment by coordinating physical delivery with programmed gene expression. For example, a hydrogel-integrated ligand may activate an artificial receptor expressed by the engineered cells and induce expression of a fate-stabilizing or maturation-promoting payload while the cells are associated with the hydrogel. As the hydrogel degrades or remodels, receptor activation may decrease, thereby reducing payload expression after an initial period of support.
[0205] Viability, engraftment, and neurite support may be evaluated using any suitable assay. Representative readouts include cell viability, cell retention, neurite extension, neuronal morphology, receptor activation, reporter expression, fate-stabilizing payload expression, ligand retention, hydrogel persistence or degradation, expression of mDA progenitor markers, expression of maturation markers, and expression of dopaminergic markers. Suitable markers include OTX2, FOXA2, LMX1A, EN1, ALDH1A1, tyrosine hydroxylase, CALB1, or other markers informative of mDA lineage identity, maturation, or dopaminergic subtype state.IX. Methods of MakingA. Lentiviral
[0206] The engineered iPSC-derived mDA progenitor cells described herein may be prepared using lentiviral gene delivery. Lentiviral methods generally involve producing lentiviral particles comprising a transfer vector encoding one or more genetic components, contacting target cells with the viral particles under transduction conditions, replacing viral medium with fresh culture medium, and selecting, enriching, expanding, sorting, or characterizing the engineered cells. The lentiviral vector may encode an artificial receptor, a receptor-responsive expression cassette, a therapeutic payload, a fate-stabilizing payload, a maturation-promoting payload, a reporter, a selectable marker, or a combination thereof.
[0207] Preferably, lentivirus is produced by transfecting producer cells with a transfer vector, a packaging vector, and an envelope vector. In some configurations, the producer cells are Lx293T cells, and transfection is performed using a lipid-based transfection reagent. Viral supernatant may be collected after transfection, filtered, pooled, concentrated, used for cell transduction, or stored. Target cells may be transduced by contacting the cells with viral medium, optionally supplemented with a transduction enhancer such as polybrene, followed by replacement with fresh medium.524921-5119-9043, v. 2
[0208] In some configurations, iPSCs are differentiated toward an mDA progenitor state before lentiviral engineering. For example, KOLF2.1J iPSCs may be differentiated into mDA progenitor cells, and the differentiated cells may be engineered by reverse transduction with a lentiviral vector encoding a TNF-responsive receptor and a receptor-responsive expression cassette. The receptor-responsive expression cassette may encode reporter outputs, including mCherry or firefly luciferase, a constitutive marker such as BFP, or a therapeutic pay load such as soluble TNF receptor 1 (sTNFRl).
[0209] The engineered cells may be exposed to TNF or another selected ligand to evaluate receptor activation and payload expression. Receptor activity may be assessed by reporter fluorescence, luminescence, or production of a therapeutic payload. The engineered cells may also be evaluated for inflammatory-marker expression and retention of mDA progenitor markers after transduction and ligand exposure.
[0210] Lentivirally engineered cells may also be combined with a hydrogel or other biomaterial described herein. For example, cells expressing a hydrogel ligand-responsive receptor may be associated with a ligand-functionalized hydrogel to induce expression of a reporter, therapeutic payload, fate-stabilizing factor, or maturation-promoting factor while the cells are associated with the hydrogel.B. Sleeping Beauty
[0211] The engineered iPSC-derived mDA progenitor cells described herein may also be prepared using a Sleeping Beauty transposase / transposon system. Sleeping Beauty methods generally involve introducing into a target cell a transposon comprising a genetic cassette flanked by transposon recognition sequences and a Sleeping Beauty transposase, or a nucleic acid encoding the transposase. The transposase mediates integration of the transposon cassette into the genome, thereby providing a non-viral method for generating engineered iPSCs, differentiating cells, or iPSC-derived mDA progenitor cells.
[0212] The transposon may encode an artificial receptor, a receptor-responsive expression cassette, a therapeutic payload, a fate-stabilizing payload, a maturation-promoting payload, a reporter, a selectable marker, or a combination thereof. After introduction of the transposon and transposase, engineered cells may be selected, enriched, expanded, sorted, or characterized based on receptor expression, reporter expression, selectable marker expression, payload expression, or another detectable feature.534921-5119-9043, v. 2
[0213] Preferably, KOLF2.1J iPSCs are engineered using a Sleeping Beauty transposase / transposon system to stably express artificial receptor platform elements, including receptor and transgene payload components. In some configurations, the cells are transfected with a Sleeping Beauty transposase construct and a transposon containing the receptor and payload components. Engineered cells may be selected during subcultivation and sorted based on receptor expression, including by detecting a tag appended to the receptor, such as a c-myc tag.
[0214] Sleeping Beauty methods may be used to prepare cells having hydrogel-responsive or fate-stabilizing programs. For example, KOLF2.1J iPSCs may be engineered to express a GFP-responsive receptor and activated by dimeric EGFP or by a GFP -functionalized hydrogel. Sleeping Beauty methods may also be used to introduce inducible fate-stabilizing payloads, including NURR1 or SOX6, which may be evaluated during differentiation toward an mDA lineage. Such engineered cells may be differentiated toward an mDA progenitor state and combined with a ligand-functionalized hydrogel to regulate expression of a reporter, fatestabilizing factor, or maturation-promoting payload.C. piggyBac
[0215] The engineered iPSC-derived mDA progenitor cells described herein may also be prepared using a piggyBac transposase / transposon system. piggyBac methods generally involve introducing a transposon comprising genetic cargo flanked by piggyBac inverted terminal repeat sequences together with a piggyBac transposase, or a nucleic acid encoding the transposase. The transposase mediates integration of the transposon cargo into the genome of the target cell, thereby providing a non-viral method for introducing receptor, payload, reporter, selectable marker, or other genetic components into iPSCs, differentiating cells, or iPSC-derived mDA progenitor cells.
[0216] The piggyBac transposon may comprise a promoter operably linked to an artificial receptor coding sequence and a receptor-responsive expression cassette operably linked to a payload. The receptor may be responsive to TNF, a hydrogel-associated ligand, or another selected cue. The payload may encode a reporter, TNF antagonist, anti-inflammatory factor, fate-stabilizing factor, maturation-promoting factor, or other gene product described herein.544921-5119-9043, v. 2
[0217] Preferably, KOLF2.1J iPSCs are engineered using a piggyBac transposase / transposon system and then differentiated toward mDA progenitor cells. In some configurations, the cells are transfected with an all-in-one vector containing a promoter driving expression of a TNF-responsive receptor and a receptor-responsive payload comprising reporter outputs. The engineered cells may be differentiated using an mDA progenitor differentiation protocol, including an E6 transition protocol, exposed to TNF, and assessed for luminescence activity as a readout of receptor-regulated reporter expression.
[0218] piggyBac methods may be useful where receptor expression or inducibility is desired through differentiation. For example, iPSCs may be engineered with a piggyBac construct encoding a TNF-responsive receptor and a receptor-responsive payload, differentiated into mDA progenitor cells, and evaluated for ligand-responsive activation. piggyBac-engineered cells may also be combined with a ligand-functionalized hydrogel so that receptor activation occurs while the cells are associated with the hydrogel. The resulting cells or cell-hydrogel compositions may be evaluated for receptor activation, payload expression, hydrogel ligand responsiveness, mDA lineage marker expression, maturation marker expression, viability, or neurite extension.X. Methods of TreatmentA. CNS Implantation and Dopaminergic Cell Replacement Therapy
[0219] The present disclosure provides methods of treating a subject by administering to the subject an engineered iPSC-derived mDA progenitor cell, a population of engineered iPSC-derived mDA progenitor cells, a cell-hydrogel composition, or an implantable device comprising the engineered cells. In some configurations, the subject has, is suspected of having, or is at risk of developing Parkinson’s disease or another condition associated with loss, dysfunction, or insufficient activity of midbrain dopaminergic neurons.
[0220] The engineered cells may be delivered to a central nervous system tissue site by injection, implantation, stereotactic administration, catheter-based delivery, surgical placement, or another suitable CNS -compatible delivery technique. The engineered cells may be administered as a cell suspension, as cells associated with a hydrogel, as cells associated with a granular hydrogel comprising hydrogel microparticles, as cells positioned within an interstitial pore network, as an implantable cell-hydrogel composition, or as another implantable or injectable composition suitable for CNS delivery.554921-5119-9043, v. 2
[0221] In some configurations, the engineered cells are delivered to a site selected to support dopaminergic cell replacement, restoration of dopaminergic signaling, or support of neural circuitry affected by Parkinson’s disease. The cells may be delivered alone or in association with a hydrogel or other biomaterial configured to support local retention, viability, engraftment, neurite extension, maturation, or receptor-mediated activation of a therapeutic or fate-stabilizing program. The hydrogel may also reduce physical disruption associated with administration and may provide a local environment that supports survival or maturation during an initial post-delivery period.
[0222] The methods may comprise administering an effective amount of engineered cells effective to provide a therapeutic benefit. A therapeutic benefit may include increased survival of administered cells, improved engraftment, improved maturation toward an mDA neuronal phenotype, increased dopaminergic marker expression, enhanced neurite extension, reduced inflammatory stress, reduced TNF-mediated signaling, local production of a therapeutic payload, local production of a fate-stabilizing payload, or preservation of a desired mDA lineage state after delivery. In the context of Parkinson’s disease, a therapeutic benefit may also include supplementation, replacement, or support of dopaminergic neuronal function.
[0223] The administered cells may be at an mDA progenitor stage, a precursor neuron stage, a differentiating mDA lineage stage, or another stage suitable for transplantation and maturation after delivery. In some configurations, the engineered cells retain mDA progenitor markers before administration and are capable of further maturation after administration. The cells may be administered in a single dose or in multiple doses and may be delivered to one or more CNS sites. The cell number, concentration, hydrogel amount, device configuration, delivery route, and administration schedule may be selected based on the subject, disease state, target tissue site, desired engraftment, desired payload activity, and intended duration of cell support.
[0224] The methods may further comprise evaluating the subject or administered cells after treatment. Evaluation may include assessing cell survival, cell retention, engraftment, neurite extension, receptor activation, payload expression, hydrogel persistence or degradation, inflammatory marker expression, mDA progenitor marker expression, maturation marker expression, dopaminergic marker expression, dopamine-564921-5119-9043, v. 2associated function, motor function, or another clinical, histologic, molecular, imaging, or functional readout relevant to treatment.B. TNF-Responsive Anti-Inflammatory and mDA Fate-Maintenance Therapy
[0225] The methods of treatment may further comprise reducing inflammation, enhancing survival, promoting maturation, or maintaining mDA fate of the administered engineered cells by activating one or more programmed therapeutic responses. In some configurations, the engineered cells comprise an artificial receptor responsive to TNF, a ligand integrated in a hydrogel, or another selected extracellular cue. Activation of the receptor may induce expression of a TNF antagonist, an anti-inflammatory payload, a fate-stabilizing factor, a maturation-promoting factor, or a combination thereof.
[0226] In some configurations, the engineered cells are configured to reduce TNF-mediated inflammation after administration. TNF may be present in a transplantation microenvironment and may contribute to inflammatory stress, impaired survival, or altered maturation of administered mDA lineage cells. The engineered cells may sense TNF and respond by expressing a TNF antagonist. Suitable TNF antagonists include soluble TNF receptor 1 (sTNFRl), an anti-TNF binding domain, a TNF-binding antibody fragment, a TNF-binding nanobody, a TNF-binding single-chain variable fragment, a TNF receptor-derived binding domain, or another agent capable of reducing TNF availability or TNF-mediated signaling.
[0227] In some configurations, the engineered cells reduce TNF-mediated inflammation through receptor-mediated TNF binding, payload-mediated TNF antagonism, or both. A TNF-sensitive receptor comprising a TNF-binding extracellular domain may bind TNF in the local environment and reduce availability of TNF for endogenous TNF receptors. Activation of the same or another receptor may also induce expression of sTNFRl or another TNF antagonist. In this manner, the administered cells may provide a localized antiinflammatory response that is activated or enhanced in a TNF-containing microenvironment.
[0228] The methods may also comprise promoting maturation or maintaining mDA fate of the administered cells. In some configurations, activation of an artificial receptor induces expression of a fate-stabilizing or maturation-promoting factor. Suitable factors include WNT ligands, WNT1, WNT3A, NURR1, SOX6, and other factors that support mDA progenitor identity, dopaminergic lineage progression, dopaminergic functional marker 574921-5119-9043, v. 2expression, substantia nigra-like or A9-like characteristics, or persistence of a desired mDA phenotype after delivery.
[0229] In some configurations, the fate-stabilizing or maturation-promoting factor is expressed in response to a hydrogel-associated ligand. For example, the engineered cells may be delivered in association with a hydrogel comprising GFP, dimeric GFP, a GFP-derived ligand, or another ligand integrated in or associated with the hydrogel. The ligand may activate an artificial receptor expressed by the engineered cells and thereby induce expression of a fate-stabilizing factor while the cells remain associated with the hydrogel. As the hydrogel degrades, remodels, disperses, or otherwise reduces ligand presentation, activation of the receptor may decrease, thereby reducing expression of the corresponding payload as the cells mature.
[0230] In other configurations, the fate-stabilizing or maturation-promoting factor is expressed in response to TNF or another inflammatory cue. Such configurations may be useful where inflammation threatens both survival and lineage stability of the administered cells. A TNF-responsive program may therefore induce an anti-inflammatory payload, a fatestabilizing pay load, or both. For example, TNF exposure may induce expression of sTNFRl to reduce TNF-mediated inflammation and may also induce or be combined with expression of WNT1, WNT3A, NURR1, SOX6, or another factor that supports mDA maturation or maintenance.
[0231] The methods may include use of cells comprising a single therapeutic program or multiple therapeutic programs. In some configurations, the cells comprise a TNF-responsive anti-inflammatory program. In other configurations, the cells comprise a hydrogel ligand-responsive fate-stabilizing program. In further configurations, the cells comprise both a TNF-responsive program and a hydrogel ligand-responsive program, allowing the cells to respond to inflammatory cues and biomaterial-associated cues during the same treatment period. Such configurations may support survival, reduce inflammatory signaling, promote maturation, and maintain mDA lineage identity after implantation.
[0232] The effectiveness of the anti-inflammatory and fate-maintenance therapy may be evaluated by measuring TNF pathway activity, inflammatory marker expression, CCL2 expression, cell survival, receptor activation, payload expression, mDA progenitor marker expression, maturation marker expression, dopaminergic marker expression,584921-5119-9043, v. 2neurite extension, engraftment, or persistence of an mDA lineage state. Representative mDA lineage and maturation markers include 0TX2, F0XA2, LMX1A, EN1, ALDH1A1, tyrosine hydroxylase, CALB 1, or other markers informative of mDA progenitor identity, dopaminergic maturation, or dopaminergic subtype state.XI. Definitions
[0233] As used herein, “engineered,” when used in reference to a cell, refers to a cell that has been modified to include, express, or regulate one or more heterologous nucleic acid sequences, receptors, response elements, transgenes, payloads, selectable markers, reporter sequences, or combinations thereof.
[0234] As used herein, “mDA progenitor cell,” “mDA precursor neuron,” “midbrain dopaminergic progenitor cell,” and related terms refer to a cell that is committed to, differentiating toward, or capable of further maturation into a midbrain dopaminergic neuronal cell.
[0235] As used herein, “artificial receptor” refers to a non-naturally occurring, recombinant, synthetic, chimeric, or engineered receptor configured to bind a selected ligand and produce a selected cellular response.
[0236] As used herein, “activation,” when used in reference to an artificial receptor, refers to a ligand-dependent or cue-dependent event that results in a detectable or functional cellular response.
[0237] “TNF-sensitive receptor” or “artificial TNF-sensitive receptor” refers to an artificial receptor comprising a TNF-binding domain and configured to bind TNF and produce a selected cellular response.
[0238] “TNF-binding domain” refers to a binding moiety capable of binding TNF.
[0239] As used herein, “transgene” and “payload” refer to a nucleic acid sequence or encoded gene product expressed by an engineered cell to produce a selected output.
[0240] As used herein, “receptor-responsive expression cassette” refers to a nucleic acid construct comprising one or more regulatory elements operably linked to a 594921-5119-9043, v. 2transgene, wherein expression of the transgene is increased, decreased, induced, or otherwise regulated in response to activation of an artificial receptor.
[0241] “TNF antagonist” refers to an agent that binds TNF, sequesters TNF, reduces TNF availability, inhibits TNF receptor engagement, reduces TNF-mediated signaling, or otherwise antagonizes one or more biological activities of TNF.
[0242] “Fate-stabilizing factor” refers to a gene product that promotes, maintains, enhances, or stabilizes one or more characteristics of an mDA progenitor cell or mDA neuronal lineage cell.
[0243] As used herein, “associated with,” when used in reference to a cell and a hydrogel, means that the cell is physically combined with, contacted with, disposed on, disposed in, adhered to, encapsulated within, seeded into, entrapped within, embedded in, suspended in, mixed with, retained by, or otherwise positioned relative to the hydrogel.
[0244] As used herein, “encapsulated within,” “seeded into,” “entrapped within,” “embedded in,” and related terms, when used in reference to a cell and a hydrogel, refer to physical placement of the cell in, on, within, among, or throughout the hydrogel or a portion thereof, and do not require complete enclosure of each individual cell by hydrogel material unless expressly stated.
[0245] As used herein, “interstitial pore network” refers to spaces, voids, pores, channels, or interconnected regions formed among hydrogel microparticles in a granular hydrogel.
[0246] “Nucleic acid,” “nucleic acid sequence,” “oligonucleotide,” “polynucleotide” or other grammatical equivalents as used herein means at least two nucleotides, either deoxyribonucleotides or ribonucleotides, or analogs thereof, covalently linked together. Polynucleotides are polymers of any length, including, e.g., 20, 50, 100, 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A polynucleotide described herein generally contains phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least one different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphophoroamidite linkages, and peptide nucleic acid backbones and linkages. Mixtures of naturally occurring polynucleotides and analogs can be604921-5119-9043, v. 2made; alternatively, mixtures of different polynucleotide analogs, and mixtures of naturally occurring polynucleotides and analogs may be made. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, cRNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The term also includes both double- and single-stranded molecules. Unless otherwise specified or required, the term polynucleotide encompasses both the double-stranded form and each of two complementary single-stranded forms known or predicted to make up the double-stranded form. A polynucleotide is composed of a specific sequence of four nucleotide bases: adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the alphabetical representation of a polynucleotide molecule. Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions may be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.
[0247] The terms “peptide,” “polypeptide” and “protein” used herein refer to polymers of amino acid residues. These terms also apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers. In the present case, the term “polypeptide” encompasses an antibody or a fragment thereof.
[0248] As used herein, “essentially free,” in terms of a specified component, is used herein to mean that none of the specified component has been purposefully formulated into a composition and / or is present only as a contaminant or in trace amounts. The total amount of the specified component resulting from any unintended contamination of a composition is 614921-5119-9043, v. 2therefore well below 0.05%, preferably below 0.01 %. Most preferred is a composition in which no amount of the specified component can be detected with standard analytical methods.
[0249] As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an” may mean one or more than one.
[0250] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” As used herein “another” may mean at least a second or more.
[0251] Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device, the inherent variation in the method being employed to determine the value, the variation that exists among the study subjects, or a value that is within 10% of a stated value.
[0252] Other terms used in the fields of recombinant nucleic acid technology, immunology, antibody engineering, and molecular and cell biology as used herein will be generally understood by one of ordinary skill in the applicable arts.XII. Examples
[0253] The following examples are included to demonstrate preferred embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of embodiments and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.Example 1: Attenuating Inflammation in Midbrain Dopaminergic Neurons through TNF-Responsive Synthetic Receptors
[0254] Materials and Methods: The inventors’ system leverages a synthetic intramembrane proteolysis receptor (SNIPR) platform to program cellular responses to cues in their microenvironment. SNIPR is a synthetic juxtacrine receptor that regulates ligand-624921-5119-9043, v. 2dependent transcriptional programs in cells through user-defined recognition motifs and transcription factors. By exchanging extracellular and intracellular domains, the inventors can produce custom receptors that can sense a variety of ligands and respond in an orthogonal manner. Here, the inventors engineered differentiated mDa neurons with SNIPR receptors to respond to TNF and produce therapeutic proteins.
[0255] Results and Discussion: KOLF2.1J iPSCs were differentiated into mDa progenitor neurons through an established 11 -day protocol. They were then lentivirally transduced with a TNF-sensitive synNotch receptor and a response element for either reporter outputs, like mCherry protein and firefly luciferase, or therapeutic outputs, like soluble TNF receptor 1 (sTNFRl), a TNF antagonist. After 72 hours of TNF treatment, engineered mDa neurons were fixed and stained for progenitor markers (Fig. 1 A). Engineered neurons showed hallmarks of mDa progenitor differentiation after lentiviral transduction. The SNIPR receptor demonstrated potent reporter activation, in the form of firefly luminescence and mCherry fluorescence, in response to TNF treatment (Fig. IB and 1C). Significant production of the therapeutic protein sTNFRl was measured as well, demonstrating that a cytokine antagonist can be produced in response to a native inflammatory marker by an engineered mDa neuron (Fig. ID). See also Appendices 1-4.
[0256] Conclusions: Here the inventors present an innovative method to address transplantation-induced inflammation in mDa neurons through a TNF-sensitive synthetic receptor. They successfully engineered neurons that retained mDa progenitor markers and showed significant activation in response to a native cytokine. Up to 30 ng / mL of a cytokine antagonist was produced, which, based on prior work, could provide a measurable benefit. Further work will involve in vitro testing to quantify reductions in inflammation and cell death via inducible TNF antagonism as well as in vivo implantation of engineered mDa neurons.Example 2: Identification of TNF-sensitive synNotch
[0257] Materials and Methods: Plasmids and Cloning. Plasmids were constructed using NEB HiFi DNA Assembly Mix (New England Biolabs) and were subsequently transformed into DH5a competent cells. Cultures were plated on LB Agar + Ampicillin (Sigma) and grown overnight at 37°C. Colonies were picked and validated via whole plasmid sequencing (Plasmidsaurus).634921-5119-9043, v. 2
[0258] Virus production. Lentivirus was produced by transfecting Lx293T cells (Clontech) with 2 pg of transfer vector, 1.5 pg of pCMV-dR8.91 packaging vector (Zufferey, R., et al., 1997) and 0.6 pg of pMD2.G envelope vector (Salmon, P., et al., 2007) (Addgene #12259) using Lipofectamine 3000 (Thermo Scientific) following manufacturer's instructions. 16 hours later, medium was exchanged for fresh DMEM-High Glucose supplemented with GlutaMAX and sodium pyruvate + 10% heat-inactivated FBS. 24 and 48 hours later, viral supernatant was collected, filtered with a 0.45 pm PVDF filter (CELLTREAT) and pooled for cell transduction or stored short-term (<1 week) at 4°C or longterm at -80°C.
[0259] Dimeric EGFP (dEGFP) production and purification. dEGFP Cloning: A mutated superfolder GFP sequence was used as the basis of the GFP dimer for copper-mediated disulfide-based dimerization, based on a previously reported amino acid sequence. Two naturally occurring cysteines, C48 and C70, were mutated to alanine to reduce off-target disulfide bonds, while the aspartic acid residue, DI 17, was mutated to cysteine for disulfide bonding. In addition, a His-tag was added for protein purification. The mutated superfolder GFP coding sequence was produced through Thermo Fisher Scientific’s GeneArt service and cloned into a pBH4 backbone for protein production.
[0260] Protein expression. Plasmids containing the mutant GFP dimer sequence were transformed into BL21-DE3 E. coli competent cells (NEB) and plated on an LB+agar with ampicillin supplementation plate for overnight incubation at 37°C. Colonies were then picked for three 4 mL starter cultures to be grown with ampicillin supplementation overnight at 37 °C. The next day, the starter cultures were added into IL of LB broth supplemented with ampicillin and allowed to grow at 37°C until the OD was measured in the 0.6-0.8 range. The culture was then induced with 1 mM IPTG (Gold Bio) and incubated for another 4 hours at 37°C. Then the culture was spun down at 4000xg for 20 minutes to harvest the cells. The pellets were then consolidated into 5 mL of PBS and then spun down again at 4000xg for 10 minutes. Pellets were frozen and stored at -20°C for up to 2 months before purification. Cell pellets were lysed using the BugBuster (Novagen) reagent. Briefly, the wet weight of the pellet was determined, and 5 mL of BugBuster reagent was added per 1.5 g of pellet. 10 pL of Lysonase reagent was then added to the suspension, which was then incubated at room temperature for 30 minutes on a rotating mixer. To remove insoluble cell debris, the suspension was then centrifuged at 4000xg for 1 hour at 4°C.644921-5119-9043, v. 2
[0261] Protein purification. His-tagged protein was isolated using a cobalt resin column. After the suspension was passed through the gravity column, the column was washed with one column volume wash buffer (20 mM Tris-HCl, 150 mM NaCl, 10 mM imidazole). The protein was then collected in fractions using elution buffer (20 mM Tris-HCl, 150 mM NaCl, 250 mM imidazole). Fractions were pooled and then concentrated into 1 mL buffer (20 mM Tris pH 9.0, 100 mM NaCl) using Amicon molecular weight cutoff (MWCO) filters (Sigma-Aldrich).
[0262] Dimerization. The GFP protein was then induced to form disulfide bonds using 10 mL dimerization buffer (20 mM Tris pH 9.0, 100 mM NaCl, 5 mM CuSO4). The reaction was allowed to proceed for 15 minutes at room temperature until quenching by addition of 50 mM EDTA. The protein was then exchanged into anion exchange buffer (10 mM Tris pH 9.5, 1 mM EDTA) using Amicon MWCO filters. Using an anion exchange column (Cytiva), the dimers were purified from the monomers via a salt gradient of 0-1 M NaCl in anion exchange buffer. Fractions were collected and validated using non-reducing SDS-PAGE. Fractions containing GFP dimers were desalted into DPBS using Amicon MWCO filters and aliquoted and frozen at -80°C.
[0263] Murine Mesenchymal Stem Cells. Bone-marrow derived C57BL / 6 mMSCs (Cyagen) were cultured in MEM-a + GlutaMAX (Gibco) supplemented with 15% FBS in an incubator at 37°C and 5% carbon dioxide. For routine subcultivation, cells were rinsed with IX DPBS (Gibco) and treated with TrypLE for five minutes at 37°C to detach cells. After quenching cells with complete medium, they were spun at 300xg for 5 minutes and replated in culture medium.
[0264] L929 Fibroblasts. Mouse L929 fibroblasts (ATCC# CCL-1) were cultured in DMEM + GlutaMAX (Gibco) supplemented with 10% heat-inactivated FBS in an incubator at 37°C and 5% carbon dioxide. For routine subcultivation, cells were treated with TrypLE for five minutes at 37°C to detach cells. After quenching cells with complete medium, they were spun at 300xg for 5 minutes and replated in culture medium.
[0265] Lentiviral Transduction. All cell lines were produced using reverse transduction using virus concentrated with LentiX Concentrator (Takara). Viral media was supplemented with 4 pg / mL of polybrene to enhance transduction efficiency and incubated with cells overnight at 37°C before being replaced with fresh cell culture media. Cells were 654921-5119-9043, v. 2selected using 10 pg / mL of puromycin (Sigma) when applicable. Unless otherwise noted, all cells following transduction were sorted for synNotch and transgene expression via fluorescence activated cell sorting (FACS).
[0266] Material-free activation of cytokine responsive synNotch receptors. mMSCs were co-engineered with synNotch receptors with scFvs that each bind to one of TNF-a, TGF- 1, IL- 1 [3 or IL-6 and a transgene cassette expressing a tetracycline response element (TRE) driven mCherry and luciferase output. 8,000 cells were plated in a white-walled 96-well plate (Corning) and treated with their respective ligands: TNF-a (25 ng / mL, StemCellTech), TGF-pi (50ng / mL, StemCellTech), IL-ip (10 ng / mL, MedChemExpress) or IL-6 (10 ng / mL, MedChemExpress). After 48 hours, CellTiter-Fluor (Promega) was performed according to manufacturer’s instructions and read on a Tecan Infinite Ml 000 Pro plate reader. Following this, a BrightGlo (Promega) assay measuring firefly luminescence as a measure of synNotch activity was performed according to manufacturer’s protocol on a Tecan Infinite M1000 Pro plate reader. Normalization was performed by dividing luminescence values each well’s respective CellTiter-Fluor output.
[0267] GFP Dimer Activation Assay. synNotch L929 fibroblasts were plated at a density of 18,000 cells / well (56,250 cells / cm2) on a control surface of streptavidin only. The LaG16 (Kd of 0.7 nM) synNotch receptor was exposed to a range of concentrations from 0 to 100 nM of either recombinant GFP purified from E. coli via immobilized metal affinity chromatography or mutant purified GFP dimer (purification process described above). After 48 hours, firefly luminescence was measured using the BrightGlo luminescence assay (Promega) on a Tecan Infinite M1000 Pro plate reader. Results are expressed as fold change relative to GFP-free conditions.
[0268] Flow Cytometry. All quantitative flow cytometry was performed on Amnis Cellstream flow cytometer. Cells were resuspended in DPBS supplemented with 2% FBS. Fluorescence activated cell sorting (FACS) was performed at the Vanderbilt Flow Core using a BD 5 Laser FACS Aria. Antibodies were diluted according to manufacturer’s instructions for all samples.
[0269] Statistical analysis. Graphs were produced using GraphPad Prism 10. All bar graphs display the mean of triplicate values with errors bars showing the standard deviation. To determine significance in experiments, a two- or three-way ANOVA with an 664921-5119-9043, v. 2alpha of 0.05 was used to compare between groups as needed. ANOVA tests were conducted along with Tukey’s post-hoc test with multiple comparisons.
[0270] Material-free activation of VEGF-responsive synNotch receptors.L929 fibroblasts were co-engineered with synNotch receptors with a VEGF binding scFv (not shown) and a transgene cassette expressing a tetracycline response element (TRE) driven luciferase output. 9,000 cells were plated in a white-walled 96-well plate (Corning) and treated with 25 ng / ml of VEGF (StemCellTech). After 48 hours, CellTiter-Fluor (Promega) was performed according to manufacturer's instructions and read on a Tecan Infinite M1000 Pro plate reader. Following this, a BrightGlo (Promega) assay measuring firefly luminescence as a measure of synNotch activity was performed according to manufacturer’s protocol on a Tecan Infinite Ml 000 Pro plate reader. Normalization was performed by dividing luminescence values each well’s respective CellTiter-Fluor output.
[0271] Maintenance of KOLF2.1J induced pluripotent stem cells.KOLF2.1J (Pantazis et al., Cell Stem Cell 2022) stem cells were maintained in StemFlex (Gibco) in Geltrex (Gibco)-coated wells. Routine cell passages were carried out using ReLeSR (Stem Cell Technologies) to detach cells. For experiments, cells were dissociated into a singlecell suspension using Accutase (Gibco).
[0272] Establishing synNotch-KOLF2.1J iPSC line. KOLF2.1J iPSCs were engineered to stably express synNotch platform elements (i.e., receptor and transgene payloads) via a Sleeping Beauty transposase / transposon system. Using the TransIT®-LTl Transfection Reagent (Minis, #MIR 2300), 1 pg of the Sleeping Beauty lOOx transposase (Addgene 34879, a kind gift from Zsuzsanna Izsvak) 46 and 1 pg of the transposon containing the synNotch receptor and transgene payloads were transfected into the iPSCs. Approximately 1 x 106 cells / mL were plated into a Geltrex -coated well in a 6-well plate and allowed to incubate with the DNA complexes for 24 hours at 37°C in StemFlex medium supplemented with 10 pM Y-27632 ROCK inhibitor (Tocris, #1254). After 24 hours, medium was replaced with fresh media. Engineered cells were selected with 0.6 pg / mL puromycin during subcultivation and sorted at the Vanderbilt Flow Cytometry Shared Resource with a 4-laser FACSAria 111 based on receptor expression using a c-myc-tag epitope appended to the synNotch receptor.674921-5119-9043, v. 2
[0273] Activation of synNotch engineered iPSCs. To activate the GFP-responsive, LaG16 synNotch iPSCs, the inventors supplemented StemFlex media with 0, 1, 5, 10, 50, 100, 500, or 1000 nM of dimeric EGFP. Dimeric EGFP was supplemented in the media when cells were plated and mCherry expression was assessed after 48 hours. To quantify mCherry expression, cells were fixed with 4% paraformaldehyde in DPBS for 10 minutes, blocked and (5% FBS and 0.3% Triton X in DPBS), and incubated with mCherry primary antibody overnight at 4°C. Cells were then washed three times with DPBS before incubation with an Alexa Fluor 647 -conjugated Donkey anti-rabbit IgG secondary antibody and the nuclear stain DAPI (Thermo Scientific, 62247, 1:1000). Cells were protected from light and incubated for 1 hour at room temperature. Cells were then washed with DPBS three times prior to imaging cells on a Leica Dmi8 microscope.
[0274] ImageJ analysis. Mean mCherry pixel intensity was calculated using ImageJ / Fiji software using built-in functions. Briefly, fluorescent images were converted to 8-bit greyscale images. DAPI channel images were used to develop a region of interest (ROI) that was used to measure the mean grey value in the mCherry channel. The ROI was made by subtracting out background noise (rolling ball radius = 50) and thresholding the greyscale image, to make a binary mask. Nuclei were then defined using the watershed feature prior to using the default analyze particles function to add the DAPI mask to the ROI manager. The ROI was then overlayed on the greyscale mCherry images to calculate the mean grey value for each nucleus. These values were then averaged to obtain the mean mCherry pixel intensity per nucleus.
[0275] Results and Discussion: To develop a platform that enables potent artificial signaling in response to native growth factors and disease-dysregulated cytokines, the inventors selected a small panel of cytokines including TGF-pi, TNF, IL-ip, and IL-6 as candidates whose signaling could be meaningfully commandeered for regenerative medicine purposes. The inventors derived single chain variable fragments (scFvs) from antibodies previously characterized to bind each of these factors (Table 1). This panel of scFvs was employed to yield a corresponding suite of receptors to allow engineered MSCs to recognize each cytokine as ligand for synNotch. The inventors first screened whether treatment of any of these MSCs with their respective synNotch ligand resulted in receptor activation in the absence of material surface functionalization. The inventors treated the separate synNotch cells with their respective ligand and measured activity of the synNotch-regulated transgene firefly 684921-5119-9043, v. 2luciferase. As expected, treatment with soluble IL-1 p and IL-6 did not activate corresponding synNotch MSCs. However, the inventors were surprised to find that both TGF-pi and TNF stimulated artificial signaling in cognate synNotch MSCs to a level of 11-fold and 24-fold, respectively, independent of material-mediated ligand capture and presentation (FIG. 2A). Anti-VEGF synNotch expressing L929 fibroblasts also demonstrated artificial signaling when supplemented with soluble VEGF in the absence of an immobilizing surface (FIG. 3). This finding contradicts prior reports describing synNotch as a juxtacrine-like signaling channel that requires ligand immobilization to potentiate signaling and that it is non-responsive to free, soluble inputs. (Piraner, D. I., et al., 2025; Lee, J. C., et al., 2023; Vamum-Finney, B., et al., 2000) IL-ip and IL-6 are, like previous inputs we and others have reported on, monomeric signaling factors, while TGFP-1 TNF, and VEGF are multimeric ligands (dimer, trimer and dimer, respectively (Huang, T., et al., 2011; Smith, R. A., et al., 1987; Muller, Y. A., et al., 1997)). Thus, we reasoned that ligand multimerization may enable capture and subsequent presentation to induce synNotch activation independent of biomaterial functionalization. To test this hypothesis, we introduced mutations into enhanced GFP (EGFP), which we previously used for material-dependent signaling via MATRIX, to adapt it into a dimeric ligand (dEGFP).(Leibly, D. J., et al., 2015) We then treated GFP-sensitive synNotch engineered MSCs with a range of concentrations of dEGFP or wild-type EGFP. The 5 nM concentration of dEGFP rendered dramatic activation of cells expressing the high-affinity, GFP-sensitive LaG16-synNotch (LaG16-Notch) receptor, while wild-type EGFP did not stimulate substantial signaling at any tested concentration (FIG. 2B), consistent with prior reports (Morsut, L., etal., 2016; Lee, J. C., et al., 2023). The inventors similarly found that dEGFP functions as a productive ligand for KOLF2.1J human induced pluripotent stem cells expressing the LaG16-Notch receptor, suggesting a lack of cell-type dependency on these findings (FIG. 4). These results signify that multimerization converts soluble inputs into those that can productively activate synNotch signaling, while confirming that monomeric inputs such as IL-ip and IL-6 require an alternative mechanism of capture and presentation.694921-5119-9043, v. 2Table 1. Antibody variable fragments used to produce synNotch receptors.scFv Target KdTNF3E (Kargbo, R. TNF 16pMB„ 2024)PET1074B9 TGF-pi Not reported(Rosales, A. M., etal., 2016)G6-31 (Kirschner, C. VEGF 0.9nMM., et al., 2013;Guvendiren, M., etal., 2012)Canakinumab IL-ip 4.1nM(Martin, J. R., el al.,2014)Ziltivekimab (Martin, IL-6 0.52nMJ. R., etaL, 2020)Gevokizumab IL-ip 0.29nM(Martin, J. R., et al.,2014)Olokizumab (Wu, Y, IL-6 lOpMet al., 2022)Example 3: Enhancing the TNF-sensitive Synthetic Receptor
[0276] Materials and Methods: Plasmid Design and Construction. Plasmids were designed with Snapgene and constructed using New England Biolabs HiFi DNA assembly mix. After assembly, plasmids were transformed into NEB5D E. coli competent cells (NEB) and plated on an LB+agar with ampicillin supplementation plate for overnight incubation at 37°C. Appropriate colonies were then picked and cultured in LB with ampicillin supplementation overnight prior to miniprep purification (Qiagen). All plasmids were verified by Sanger sequencing prior to use.
[0277] Lentivirus was produced by transfecting Lx293T cells (Clontech) with 2 mg of transfer vector, 1.5 mg of pCMV-dR8.91 packaging vector and 0.6 mg of pMD2.G envelope vector (gift from Didier Trono, Addgene #12259) using Lipofectamine 3000 (Thermo Scientific) following manufacturer’s instructions. The following day, medium was exchanged for fresh DMEM-High Glucose supplemented with GlutaMAX and sodium pyruvate as well as 10% heat-inactivated FBS. On each of the following two days, viral supernatant was704921-5119-9043, v. 2collected, filtered with a 0.45 mm PVDF filter (CELLTREAT) and pooled for cell transduction or stored short-term (< 1 week) at 4oC or long-term at -80°C.
[0278] Murine mesenchymal stem cells. Bone marrow-derived mesenchymal stem cells from C57BL / 6 mice (Cyagen) were cultured in MEM a supplemented with GlutaMAX (Gibco) and 15% FBS in an incubator at 37°C and 5% carbon dioxide. For subcultivation, cells were rinsed with IX DPBS (Gibco) for one minute and then detached with TrypLE by incubation at 37°C for 5 minutes. Cells were then centrifuged for 5 minutes at 300 xg and resuspended in mMSC culture medium for plating.
[0279] Lentiviral transduction. mMSC lines were derived through reverse transduction by passaging and plating with 100% viral media. Media were supplemented with 4 nig / mL of polybrene to facilitate uptake of the lentiviral particles. Viral medium was incubated with target cells overnight and replaced with fresh media the next day. mMSCs were selected in 10 pg / mL puromycin where applicable prior to experiments.
[0280] TNF-synNotch vs TNF-SNIPR comparison. mMSCs were engineered with either a TNF-sensitive synNotch receptor or a TNF-sensitive SNIPR. They were then plated at a total density of 8,000 / well (25,000 cells / cm2) on a tissue-culture treated plate with medium supplemented with varying concentrations of TNF, from 0 to 100 ng / mL. Firefly luminescence was measured as noted above after 48 hours.
[0281] Comparison of TNF-SNIPRs. Three FDA-approved TNF antibodies, certolizumab (Lee, J. U., et al., 2017), ozoralizumab (Oyama, S., et al., 2022), and adalimumab (Weinblatt, M. E., el al., 2003), were cloned into a SNIPR plasmid backbone and transduced into mMSCs along with a reporter response element. The various TNF-SNIPRs were plated at a total density of 8,000 / well (25,000 cells / cm2) on a tissue-culture treated plate with medium supplemented with varying concentrations of TNF, from 0 to 100 ng / mL. After 48 hours, firefly luminescence was measured as noted above.
[0282] TNF receptor neutralization effect. mMSCs were engineered with an NFDB pathway reporter that produces GFP when activated. A portion of these mMSCs were then engineered with the TNF3E-SNIPR only. mMSCs were plated at a total density of 100,000 / well (52,632 cells / cm2) along with media supplemented with either 0, 25, or 50 ng / mL714921-5119-9043, v. 2of TNF. After 24 hours, cells were disassociated with TrypLE and prepared for flow cytometry as described below.
[0283] Flow cytometry. Cells were dissociated into a single cell suspension with TrypLE, as noted above. Cells were pelleted via centrifugation and then resuspended into blocking buffer (5% FBS in DPBS). The samples were then spun down again and resuspended in 100 DL of blocking buffer per sample. For immunolabeling prior to flow cytometry, cells were incubated for 15 minutes in blocking buffer on ice. Cells were immunolabeled with an Alexa Fluor 647 conjugated mouse monoclonal antibody for c-myc tags (clone 9B11, Cell Signaling Technologies) at a 1:100 dilution for mMSC TNF receptor neutralization experiments. After staining, the samples were then washed twice with 200 pL blocking buffer, collected by centrifugation and then resuspended for analysis in 100 pL of blocking buffer. Flow cytometry results were collected from a Cellstream analytical flow cytometer and analyzed in FlowJo.
[0284] Statistical analysis. All bar graphs display means of triplicates with error bars showing standard error of the mean. To determine significance in experiments, oneway or two-way ANOVA was used as appropriate followed by Tukey's post-hoc test with alpha set at 0.05.
[0285] Results and Discussion: The inventors first examined the architecture of their synthetic receptor, looking to see if optimization and humanization of the transmembrane components could have an effect on reporter activation. Recently, a new synthetic RIP -based receptor platform was published called synthetic intramembrane proteolysis receptors (SNIPRs) (Zhu, I., et al., 2022). These receptors have a modular extracellular and intracellular domain, but SNIPR’s transmembrane components have been optimized for ease of cellular transduction and for clinical translation with humanized components. The inventors thus compared their previously designed TNF-sensitive synNotch receptor with a TNF-sensitive SNIPR. Both contain the same extracellular TNF-binding domain and the same synthetic intracellular transcription factor for ease of comparison. Across a range of TNF concentrations, the inventors noted that the fold activation produced by the TNF-SNIPR cells was significantly higher (FIG. 5A). Based on this observation, the inventors decided to move forward with the SNIPR architecture in all further experiments, rather than the synNotch receptor structure. To further optimize their TNF-sensitive receptor, the inventors next examined the extracellular724921-5119-9043, v. 2TNF-binding domain. The inventors had been utilizing a nanobody, TNF3E (Ka=16 nM) (Silence, K., et al., 2017), but wanted to compare with FDA-approved TNF antibodies, as they have demonstrated proven therapeutic potential and productive binding to TNF in vivo. We created three other SNIPRs with the TNF antibody domains, adalimumab (Kd=0.6 nM) (Weinblatt, M. E., et al., 2003), ozoralizumab (Kd=20.2 pM) (Oyama, S., et al., 2022), and certolizumab (Kd=90 pM) (Lee, J. U., et al., 2017), and compared their performance across a range of TNF concentrations with the original TNF3E-SNIPR. The inventors observed that the TNF3E-SNIPR achieved fold induction levels of greater than 1 OOx at 50 ng / mL of TNF, while the certo-SNIPR and ozora-SNIPR had fold induction levels of around 50-fold (FIG. 5B). The adalim-SNIPR was their worst performing receptor, with fold induction levels of only lOx even at 100 ng / mL of TNF. Thus, in future experiments, the inventors decided to utilize the TNF3E-SNIPR as the optimized TNF-sensitive synthetic receptor.
[0286] The inventors next delved deeper into the therapeutic applications of their optimized TNF-sensitive receptor. The inventors hypothesized that their receptor could bind inflammatory TNF in the environment, thus reducing the available TNF and attenuating inflammation independent of transgene expression. To test the TNF neutralization capabilities of their synthetic receptor, the inventors engineered mouse mesenchymal stem cells (mMSCs) with a GFP reporter as a readout for NF-KB transcriptional activity. The NF-KB pathway is highly upregulated in inflammatory TNF signaling, so it can be used as a proxy to assess inflammatory signal transduction in reporter cells (Ward-Kavanagh, L. K., et al., 2016). The inventors then transduced a subset of these NF-KB reporter cells with the TNF3E-SNIPR only, with no payload transgene, meaning there will be no output produced when the receptor is activated. This allowed us to isolate the effect of the receptor solely. The NF-KB reporter cells and the TNF3E-SNIPR reporter cells were then exposed to a range of TNF concentrations and then stained for receptor expression. Flow cytometry was performed to assess GFP fluorescence. The inventors expected to see inflammation attenuation in the NF-KB reporter cells that also contained the TNF3E-SNIPR (FIG. 6A), and the inventors saw significantly lowered GFP expression in those cells as compared to cells with only the NF-KB reporter (FIG.6B). Thus, the inventors have developed an optimized TNF-sensitive synthetic receptor that is able to neutralize a potent pro-inflammatory cytokine and attenuate inflammation without the release of any therapeutic factors. Additionally, this optimized receptor is able to upregulate reporter activation up to 100-fold, leading us to believe that if engineered to release therapeutic734921-5119-9043, v. 2payloads, their programmed cells could both neutralize TNF and redirect cellular responses to TNF.Example 4: Function of TNF-sensitive Receptor in hPSC-derived mDA progenitors
[0287] Materials and Methods: Human induced pluripotent stem cells.KOLF2.1 J human induced pluripotent stem cells (iPSCs, The Jackson Laboratory (Pantazis, C. B., et al., 2022)) were maintained in StemFlex medium (Gibco) on Geltrex (Gibco)-coated wells. For routine passaging, cells were detached with ReLeSR (STEMCELL Technologies). To produce a single-cell suspension for differentiation experiments, cells were dissociated with Accutase (Gibco).
[0288] Lentiviral transduction. Midbrain dopaminergic (mDa) progenitors were engineered through reverse transduction. mDa neurons were passaged and plated with 50%, 100%, or 200% concentrated virus resuspended in late mDa neuron media (formulation specified below). Virus percentages refer to undiluted and unconcentrated viral medium amounts, so that 100% lenti virus medium is the original viral supernatant concentration collected from transfected cells. Viral medium was concentrated using the Lenti-X concentrator reagent (Takara Bio). Briefly, media were incubated with the reagent for at least 30 minutes at 4°C and then centrifuged at 1500 xg for 45 minutes at 4°C. Media were supplemented with 4 mg / mL of polybrene to facilitate uptake of the lentiviral particles. Viral medium was incubated with target cells overnight and replaced with fresh media the next day.
[0289] Media preparation. Base mDa neuron medium consisted of 43.2 mL neurobasal media (Gibco), 0.45 mL GlutaMax (Gibco), 0.45 mL N2 (Gibco), and 0.9 mL B27 supplement without vitamin A (Gibco).
[0290] Late mDa neuron medium was prepared by mixing 29.1 mL of neurobasal media, 0.3 mL GlutaMax, and 0.3 mL B27 supplement without vitamin A. It was then supplemented with 3 pM CHIR99021 (CHIR, StemCell Technologies), 20 ng / mL brain-derived neurotrophic factor (BDNF, PeproTech), 20 ng / mL glial cell line-derived neurotrophic factor (GDNF, PeproTech), 0.2 mM dibutyryl cyclic-AMP (cAMP, StemCell Technologies), 0.2 mM L-ascorbic acid (Sigma-Aldrich), and 1 ng / mL TGF-(33 (R&D Systems) (Kim, T. W., et al., 2021). Essential 4 (E4) basal medium (Chen, G., et al., 2011) was prepared in large744921-5119-9043, v. 2batches as a precursor for Essential 6 (E6) media by mixing L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate, sodium selenite solution, and sodium bicarbonate in DMEM / F12, HEPES (Thermo Fisher Scientific). E6 medium was prepared by adding 100 pL of human insulin solution (Sigma Aldrich) and 500 pL of 10 mg / mL Transferrin (R&D Systems) to 500 mL of E4 medium. E6 media were sterile-filtered prior to cell culture use.
[0291] Midbrain dopaminergic neuron differentiation. KOLF2.1J iPSCs were differentiated into mDa progenitor neurons as previously published (Brien, H. J., et al., 2024; Kim, T. W., et al., 2021). In the E6 transition protocol, briefly, KOLF2.1J iPSCs were plated at a density of 200,000 cells / well (181,818 cells / cm2) in a tissue-culture treated 48-well plate on day 0 in base mDa neuron medium supplemented with 250 nM LDN193189 dihydrochloride (LDN, Tocris), 10 pM SB431542 (SB, StemCell Technologies), 250 nM Smoothened Agonist (SAG, Fisher Scientific), 2 pM Punnorphamine (PM, Fisher Scientific), 10 pM Y-27672 rho-associated protein kinase (ROCK) inhibitor (Tocris), and 0.7 pM CHIR99021 (CHIR, StemCell Technologies). Culture media were changed every day as outlined in the following: 24 h after plating, the Y-27672 ROCK inhibitor was removed for the remainder of the differentiation. On day 4, the CHIR concentration was boosted to 7.5 pM until day 9. On day 7, the small molecules LDN, SB, PM, and SAG were withheld. On day 8 and 9, cells were maintained in medium composed of 50% base mDa medium and 50% E6 medium. On day 9, the small molecule LDN was re-introduced at 0.4 pM until day 10. On day 10, cells were maintained in medium composed of 25% mDa base medium and 75% E6 with a decreased CHIR concentration of 3 pM. On day 11, cells were disassociated with Accutase for lenti viral transduction.
[0292] For the Kim et al. differentiation protocol (Kim, T. W., et al., 2021), the above was followed, but cells were maintained solely in base mDa medium with no addition of E6 medium. For the maintenance media protocol, the Kim et al. differentiation protocol was followed, but on day 0, cells were plated in StemFlex media supplemented with 10 pM ROCK. As cells were plated in maintenance media on day 0, an additional day of base mDa neuron medium supplemented with 250 nM LDN, 10 pM SB, 250 nM SAG, 2 pM PM, and 0.7 pM CHIR was added at the beginning of the differentiation protocol.
[0293] Activation of mDa progenitors with TNF. At day 11, mDa neurons were replated with lenti viral media, concentrated as described above, at a density of 200,000754921-5119-9043, v. 2cells / well (181,818 cells / cm2). Progenitors were engineered with a TNF-sensitive synthetic receptor and a response element, consisting of either a reporter payload for firefly luciferase and mCherry and a constitutive BFP marker or a therapeutic payload for soluble TNF receptor 1 (sTNFRl). They were then maintained in late mDa neuron media (composition described above), with media changes every 2 days, until either day 16 or day 18. 50 ng / mL of TNF were then supplemented into the media and allowed to inflame the neurons for 72 hours. After 72 hours, reporter outputs were measured, and neurons were either lysed for RNA extraction or prepared for immunofluorescence as described below.
[0294] Microscopy. All images were taken on a Leica Dmi8 epifluorescence microscope at lOx magnification.
[0295] Luminescence. Firefly luciferase measurements were taken using D-luciferin (Thermo Scientific) to avoid cell lysis. In brief, a 150 pg / mL working dilution of D-luciferin was prepared in DPBS from a stock solution of 15 mg / mL D-luciferin stored at -80°C. Cell media was aspirated from the wells, and the working dilution was added to the wells. Measurements were taken immediately after addition of the D-luciferin using a Tecan Infinite Ml 000 Pro plate reader.
[0296] ELISA. For ELISA analysis, the Human TNF RI / TNFRSF1A DuoSet ELISA kit and DuoSet Ancillary Reagents (R&D Systems) were used. Culture media were collected off the cells and media from conditions with TNF added were diluted 1 : 100 in reagent diluent while media from conditions without TNF added were undiluted. Following the manufacturer’s protocol, absorbance measurements at 450 nm were made on a Tecan Infinite M1000 Pro plate reader, with a measurement at 540 nm to correct for plate absorbance. Average absorbance of the 0 pg / mL standard was subtracted from all samples to correct for baseline absorbance. A standard curve was determined by plotting the standard concentrations versus the absorbances and reducing the data using GraphPad Prism to generate a 4-parameter logistic curve-fit. Sample concentrations were then interpolated from the standard curve.
[0297] Quantitative real-time PCR. Cells were lysed and mRNA was isolated using the PureLink RNA Mini Kit (Invitrogen). mRNA was reverse transcribed into cDNA for qRT-PCR analysis using the SuperScript IV VILO Master Mix (Invitrogen). Samples were analyzed with the PowerTrack SYBR Green Master Mix (Applied Biosystems) on a Bio-Rad764921-5119-9043, v. 2CFX96 using a non-skirted low-profile plate (Thermo Scientific) with optical adhesive film (Applied Biosystems). Relative gene expression was calculated using the delta-delta Ct method using GAPDH as a reference gene and indicated samples as controls.
[0298] Immunocytochemistry. Cells were fixed in 4% paraformaldehyde in PBS for 15 minutes, washed in ice cold DPBS, and permeabilized and blocked in 0.3% Triton-X (EMD Millipore) and 5% FBS in PBS for 30 minutes. Cells were then incubated in primary antibody in permeabilization and blocking buffer overnight at 4°C. Antibody dilutions and sources are shown in Supplementary Table 3. The cells were then washed in DPBS twice, incubated with secondary antibody, and counterstained with a 1:1000 dilution of DAPI (Thermo Scientific) in deionized water for one hour at room temperature protected from light. Before imaging, cells were washed in DPBS twice. All antibodies were diluted in permeabilization and blocking buffer.
[0299] Statistical analysis. All bar graphs display means of triplicates with error bars showing standard error of the mean. To determine significance in experiments involving >2 groups or categorical variables, one-way or two-way ANOVA was used as appropriate followed by Tukey’s post-hoc test with alpha set at 0.05.
[0300] Results and Discussion: Engineering mDa Progenitor Neurons with Synthetic Receptors. As mDa neuron transplantation is being developed as a treatment for the neurodegenerative disease, Parkinson’s disease, the inventors sought to engineer these cells with synthetic receptors sensitive to TNF, a pro-inflammatory cytokine that mDa neurons are heavily affected by. KOLF2.1J human induced pluripotent stem cells (iPSCs) were induced to differentiate into mDa progenitor neurons through an 11-day adapted protocol from Kim et al. (Kim, T. W., et al., 2021). At the end of the differentiation protocol, the cells were replated and reverse transduced with lentiviral vectors containing the previously described TNF3E-synNotch receptor and a response element for the reporter outputs mCherry and firefly luciferase and a constitutive BFP marker to allow for visualization of engineered cells. After 72 hours to allow for full expression of the receptor platform components, the cells were treated with TNF for 24 hours (FIG. 7A). mDa progenitors treated with TNF showed increased mCherry fluorescence over mDa progenitors not treated with TNF, and engineered progenitors showed evidence of transduction through expression of a constitutive BFP marker (FIG. 7B). The inventors then stained the cells for the mDa progenitor markers, OTX2, FOXA2, LMX1 A,774921-5119-9043, v. 2and EN1, and saw that even after reverse transduction and treatment with TNF, expression of progenitor markers was still maintained (FIG. 7C). Here, the inventors demonstrated that the they can successfully engineer differentiated mDa progenitors with TNF-sensitive synthetic receptors that can productively activate in response to a pro-inflammatory ligand with significant reporter activation.
[0301] Optimization of mDa Differentiation. Although the inventors demonstrated expression of mDa progenitor markers, the inventors wanted to further test and optimize their differentiation protocol to ensure the most effective differentiation. The inventors tested three different variations of the 11 -day mDa differentiation protocol introduced by Kim et al. (Kim, T. W„ et al., 2021). Their original protocol (Brien, H. J., et al., 2024) was adapted from the Kim et al. protocol and includes a base media transition into Essential 6 (E6) medium, which has been an element in other mDa differentiation protocols (Kriks, S., et al., 2011). The inventors termed this protocol E6 transition. The inventors tested the original Kim, et al. protocol as well, along with another variation where cells were plated in StemFlex on the first day and then taken through the rest of the Kim et al. protocol, termed maintenance media (FIG. 8 A). At the end of the 11 -day differentiation, cells were replated for staining and RNA extraction. Expression of the mDa progenitor markers was consistent across all three protocols, except for noticeably lower EMX1A expression in the Kim, et al. protocol (FIG. 8B). The inventors then quantified gene expression through qPCR and observed significantly higher EN1 expression in the E6 transition protocol than in the Kim, et al. or maintenance media protocols (FIG. 8C). As both EMX1A and EN1 are important midbrain development markers, the inventors decided to move forward with the E6 transition protocol for all further experiments (Cai, J., et al., 2009; Alves dos Santos, M. T., et al., 2011; Hegarty, S. V., et al., 2013).
[0302] Optimization of Reporter Activation. After productively engineering differentiated mDa progenitors and determining the most effective differentiation protocol, the inventors wanted to look at improving the dynamic range of their receptor platform. To do this, the inventors opted to optimize reporter activation, so the inventors could easily evaluate receptor performance. The inventors first looked at their synthetic reporter architecture, evaluating if optimization and humanization of the transmembrane components could have an effect on reporter activation. Based on their prior work, the inventors had reason to believe that use of a new RIP-based synthetic receptor platform called synthetic intramembrane proteolysis 784921-5119-9043, v. 2receptors (SNIPRs) (Zhu, I., et al., 2022) could demonstrate increased fold induction. SNIPRs have a modular extracellular and intracellular domain, but their transmembrane components differ from synNotch and have been optimized for ease of cellular transduction and for clinical translation with humanized components. The inventors transduced mDa progenitors with either the previously described TNF-sensitive synNotch receptor or a TNF-sensitive SNIPR. Both utilize the TNF3E extracellular TNF-binding domain and the same synthetic intracellular transcription factor for ease of comparison (Silence, K., et al., 2017). After activation with 50 ng / mL of TNF, the inventors observed increased mCherry fluorescence in mDa progenitors with TNF3E-SNIPRs compared with those with TNF3E-synNotch receptors (FIG. 9A). Although reporter mCherry fluorescence was increased, the inventors wanted to further improve their transduction and activation. All cells were engineered with a constitutive BFP marker for visualization of transduced cells, and the inventors observed that BFP signal was sparse, indicating that the transduction was not very effective. To improve their transduction efficiency, the inventors titrated in various percentages of lentivirus from 50% to 200%. Lentivirus percentages refer to the original viral supernatant concentration, so that 100% lentivirus is the unconcentrated viral medium collected from transfected cells. The inventors then measured reporter luminescence and saw that it increased significantly with lentivirus percentage (FIG. 9B). Transduction efficiency appeared higher as well, as BFP signal in mDa neurons was less sparse and inducible mCherry fluorescence was stronger. Based on this, the inventors decided to move forward with the TNF3E-SNIPR in further experiments and increased viral percentage to 200% for optimized transgene expression and receptor activation.
[0303] Activation of Therapeutic Outputs. As their synthetic receptor system is modular, allowing for user-defined transgenes, the inventors next looked to see if they could induce expression of therapeutic proteins rather than reporter outputs. The inventors engineered mDa progenitor neurons to produce soluble TNF receptor 1 (sTNFRl). As the inventors have shown previously, sTNFRl can attenuate inflammation caused by TNF administration in vitro (Lee, J. C., et al., 2023). Additionally, it has demonstrated its potential as a TNF antagonist in previous work (Brunger, J. M., et al., 2017; Khoury, M., et al., 2007), and so we decided to deliver this therapeutic protein in response to TNF. As the maturation timeline for mDa progenitors to be transplanted in vivo is closer to 16-30 days of in vitro differentiation and culture (Kim, T. W., et al., 2021), the inventors extended their differentiation protocol so that mDa progenitors could continue to mature in late mDa neuron media (FIG. 10A). At the end794921-5119-9043, v. 2of the protocol, the inventors quantified production of sTNFRl through an ELISA and saw significant upregulation of the therapeutic transgene when engineered cells were exposed to TNF (FIG. 10B). The inventors next wanted to look at the inflammation attenuation induced in response to sTNFRl production. The inventors evaluated inflammatory gene expression using qRT-PCR and observed a reduction in the neuroinflammatory marker CCL2 in therapeutic mDa progenitor populations compared to reporter mDa progenitors (FIG. IOC). To their knowledge, this represents the first productive attempt to attenuate inflammation in mDa progenitors through programming with synthetic receptors.Example 5: Adapting the platform to a non-viral, piggyBac transposase / transposon system
[0304] Rather than engineer the KOLF2.1J iPSCs via viral transduction, the inventors have engineered the cells with a piggyBac transposase / transposon system. Cells were transfected with an all-in-one vector containing a CAG promoter driving expression of the TNF3E-SNIPR as well as a TRE-driven payload of mCherry and firefly luciferase. Cells were then differentiated to mDA progenitors as outlined previously using the E6 transition protocol. On Day 11, cells were passaged and on Day 12 cells were treated with TNF (50 ng / ml). Twenty-four hours later, they were assessed for luminescence activity as a readout of SNIPR-regulated luciferase production.Example 6: Use in combination with hydrogel to activate transgene expression for fate stabilization
[0305] A key aspect of this disclosure is that the inventors can use a hydrogel in combination with RIP-engineered stem cells to promote survival and fate stabilization of hiPSC-derived mDA progenitors. Toward this end, the inventors have produced a hydrogel that can activate expression of transgenes via a GFP -responsive synNotch RIP. GFP-synNotch KOLF2.1J hiPSCs were engineered via transposase / transposon system as described in Lee et al., Biomaterials 2023 and Brien et al., ACS Biomater Sci Eng 2024. Activated synNotch-KOLFs will upregulate mCherry expression.
[0306] The inventors conjugated GFP to the surface of (a peptide-functionalized gelatin methacryloyl) using a simple l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) / n-hydroxysuccinimide (NHS) reaction that couples the lysine on GFP to open carboxyl residues on GelMA.52 For initial 2D experimentation,804921-5119-9043, v. 2GelMA was photopolymerized with lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) in a thin layer on well plates then conjugated with 370 nM or 1850 nM GFP (GelMA-GFP) after carboxyl activation with 250 mM EDC and NHS. Conjugation is monitored via fluorescence. To show the ability of GFP-conjugated GelMA to activate synNotch, hPSCs expressing GFP -responsive synNotch that activates mCherry and firefly luciferase were plated on GelMA with no GFP, 370 nM of conjugated GFP, 1850 nM of conjugated GFP, or GelMA with media containing soluble GFP, which should not be able to activate the system since the ligand is not immobilized. SynNotch activation was monitored using fluorescence microscopy for mCherry expression. When hPSCs are plated on GelMA with or without soluble GFP there is little / no activation; however, when plated on GelMA-GFP synNotch is activated and mCherry expression emerges, with a greater number of hPSCs activated in the high conjugation condition (FIG. 12). This demonstrates the feasibility of conjugating GFP to the surface of GelMA for synthetic circuit activation with tunability based on the amount of GFP loaded into the reaction. Furthermore, the inventors have successfully conjugated GFP to the surface of GelMA hydrogel microparticles (HMPs) at 370 nM or 1850 nM (FIG. 13 A). GFP HMPs are also able activate synNotch when seeded on top GelMA (FIG. 13B).
[0307] To stabilize the fate of transplanted mDA progenitors, the inventors have engineered RIP-receptor circuits to regulate transgenes that may promote mDA fate specification. As the inventors have published (Brien et al., ACS Biomater Sci Eng 2024), one such transgene could be from the WNT family, specifically, WNT1 or WNT3A. Others, though, could be transcription factors such as NURR1 or SOX6. Thus, the inventors tested whether NURR1 or SOX6 will promote fate specification of KOLF2.1J cells to mDA neurons across a 30-day differentiation protocol (FIG. 14). KOLF2.1J cells were engineered to inducibly express NURR1 or SOX6 under control of a doxycycline (dox)-inducible promoter (Fig 15) using a Sleeping Beauty transposase / transposon system (as in Brien et al., ACS Biomater Sci Eng 2024). Dox -driven transgene expression was confirmed by fluorescence microscopy and qRT-PCR. At day 30, qRT-PCR was used to evaluate mDA fate, probing for target markers EN1 and ALDH1A1 (suggestive of the desired A9 mDA phenotype) and CALB1 (suggested of the less-desired A10 phenotype). Results suggest that SOX6 more potently supports the expression of EN1 and ALDH1A1 without enhancing CALB1 expression (FIG. 16). Furthermore, immunofluorescence microscopy probing for tyrosine hydroxylase, a key enzyme for mDA function, shows that SOX6 enhances TH expression (FIG. 17). These814921-5119-9043, v. 2results elevate SOX6 as a viable candidate pay load of a RIP-regulated gene circuit for stabilizing mDA progenitor fate and promoting further maturation after transplantation.
[0308] All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this disclosure have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the disclosure. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the disclosure as defined by the appended claims.824921-5119-9043, v. 2XIII. SequencesSEQ ID NO:1 TNF3E SNIPR Inducible Luciferase + mCherry Payload MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYA EYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDI YNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMDSKTDYQGFQS MYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVR FSHARDPIFGNQIIPDTAILSVVPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFL RSLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAK RFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLG VNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVD RLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHG KTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAK KGGKAmFSELKGAGDNEENPGPMVSKGEEDNMAIIKEFMRFKVHMEGSVNGHEFEI EGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLKLSFPE GFKWERVMNFEDGGVVTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEASS ERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDITSHNED YTIVEQYERAEGRHSTGGMDELYK* MALPVTALLLPLALLLHAARPEOKLISEEDLOVOLOESGGGLVQPGGSLRLSCAASGAAOVOLOESGGGLVOPGGSLRLSCAASGRTFSDHSGYTYTIGWFRQAPGKEREFVA RIYWSSGNTYYADSVKGRFA1SRDIAKNTVDLTMNNLEPEDTAVYYCAARDG1PTSRYWHVKNKRALLDALAIEMLDRHHTHFCPLEGESWQDFLRNNAKSFRCALLSHRDG AKVHLGTRPTEKQYETLENQLAFLCQQGFSLENALYALSAVGHFTLGCVLEDQEHQ VAKEERETPTTDSMPPLLRQAIELFDHQGAEPAFLFGLELIICGLEKQLKCESGGPAD ALDDFDLDMLPADALDDFDLDMLPADALDDFDLDMLPG*Bold = Luciferase transgeneItalicized = mCherry transgeneUnderlined = 2x TNF3EBold Italic = CD8 HingeBold Underlined = NOTCH1 TransmembraneItalic Underlined = NOTCH2 Juxtamembrane834921-5119-9043, V. 2SEQ ID NO: 2 GFP synNotch Inducible Luciferase + mCherry Payload MEDAKNIKKGPAPFYPLEDGTAGEQLHKAMKRYALVPGTIAFTDAHIEVDITYA EYFEMSVRLAEAMKRYGLNTNHRIVVCSENSLQFFMPVLGALFIGVAVAPANDI YNERELLNSMGISQPTVVFVSKKGLQKILNVQKKLPIIQKIIIMDSKTDYQGFQS MYTFVTSHLPPGFNEYDFVPESFDRDKTIALIMNSSGSTGLPKGVALPHRTACVR FSHARDPIFGNQIIPDTAILSVVPFHHGFGMFTTLGYLICGFRVVLMYRFEEELFL RSLQDYKIQSALLVPTLFSFFAKSTLIDKYDLSNLHEIASGGAPLSKEVGEAVAK RFHLPGIRQGYGLTETTSAILITPEGDDKPGAVGKVVPFFEAKVVDLDTGKTLG VNQRGELCVRGPMIMSGYVNNPEATNALIDKDGWLHSGDIAYWDEDEHFFIVD RLKSLIKYKGYQVAPAELESILLQHPNIFDAGVAGLPDDDAGELPAAVVVLEHG KTMTEKEIVDYVASQVTTAKKLRGGVVFVDEVPKGLTGKLDARKIREILIKAK KGGKRAKRAYNFSLEKGAGDNEENPGPMVSKGEEDNMAIIKEFMRFKVHMEGSVNG HEFEIEGEGEGRPYEGTQTAKLKVTKGGPLPFAWDILSPQFMYGSKAYVKHPADIPDYLK LSFPEGFKWERVMNFEDGGWTVTQDSSLQDGEFIYKVKLRGTNFPSDGPVMQKKTMG WEASSERMYPEDGALKGEIKQRLKLKDGGHYDAEVKTTYKAKKPVQLPGAYNVNIKLDIT SHNEDYTIVEQYERAEGRHSTGGMDELYK* MALPVTALLLPLALLLHAARPEOKLISEEDLMAOVOLVESGGRLVOAGDSLRLSCA ASGRTFSTSAMAWFROAPGREREFVAAITWTVGNTILGDSVKGRFTISRDRAKNTVD LOMDNLEPEDTAVYYCSARSRGYVLSVLRSVDSYDYWGQGTOVTVSZLDySFTGGA GRDIPPPQIEEA CELPECQVDA GNKVCNLQCNNHA CGWDGGDCSLNFNDPWKNCT QSLQCWKYFSDGHCDSQCNSAGCLFDGFDCQLTEGQCNPLYDQYCKDHFSDGHCD QGCNSAECEWDGLDCAEHVPERLAAGTLVLVVLLPPDQLRNNSFHFLRELSHVLHT NVVFKRDAQGQQMIFPYYGHEEELRKHPIKRSTVGWATSSLLPGTSGGRQRRELDP MDIRGSIVYLEIDNRQCVQSSSQCFQSATDVAAFLGALASLGSLN1PYK1EAVKSEPVE PPLPSQLHLMYVAAAAFVLLFFVGCGVLLSRKRRRMSRE KS NV' SAEEEE ENGV EGLTTRKLAQKLGVEQPTLYWHVKNKRALLDALAIEMLDRHHTHFCPLEGESWQDF LRNNAKSFRCALLSHRDGAKVHLGTRPTEKQYETLENQLAFLCQQGFSLENALYAL SAVGHFTLGCVLEDQEHQVAKEERETPTTDSMPPLLRQAIELFDHQGAEPAFLFGLE LIICGLEKQLKCESGGPADALDDFDLDMLPADALDDFDLDMLPADALDDFDLDMLPG*Bold = Luciferase transgeneItalicized = mCherry transgeneUnderlined = LAG16Bold Italic = synNOTCH core4921-5119-9043, v. 2SEQ ID NO: 3 TNF3E Extracellular Recognition domain (ERD) QVQLQESGGGLVQPGGSLRLSCAASGRTFSDHSGYTYTIGWFRQAPGKEREFV ARIYWSSGNTYYADSVKGRFAISRDIAKNTVDLTMNNLEPEDTAVYYCAARDGI PTSRSVESYNYWGQGTQVTVSSPP^TP / TPeP AAQVQLQESGGGLVQPGGSLRLS CAASGRTFSDHSGYTYTIGWFRQAPGKEREFVARIYWSSGNTYYADSVKGRFAI SRDIAKNTVDLTMNNLEPEDTAVYYCAARDGIPTSRSVESYNYWGQGTQVTVSSBold = 2x TNF3EItalicized = LinkerSEQ ID NO: 4 Ozoralizumab ERD EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYWMYWVRQAPGKGLEWVSEIN TNGLITKYPDSVKGRFTISRDNAKNTLYLQMNSLRPEDTAVYYCARSPSGFNRG QGTLVTVSSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSD YWMYWVRQAPGKGLEWVSEINTNGLITKYPDSVKGRFTISRDNAKNTLYLQM NSLRPEDTAVYYCARSPSGFNRGQGTLVTVSSBold = 2x Ozoralizumab Heavy ChainItalicized = LinkerSEQ ID NO: 5 Certolizumab ERD EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWI NTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMTyYWGQGTEVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTGG GGSGGGGSGGGGSDIOMTOSPSSLSASVGDR VTITCKASQNVGTNVA WYQQKPGKA PKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGT KVEIKRTVAAPSVFIFPPSDEOLKSGTASWCLLNNFYPREAKVOWKVDNALOSGNSOESV TEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVrKSFNRGECBold = Certolizumab Heavy ChainItalicized = partial Certolizumab Ig CHIUnderlined = LinkerBold Italic = Certolizumab Light ChainItalic Underlined = IgK constant854921-5119-9043, v. 2SEQ ID NO: 6 Adalimumab ERD EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAIT WNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTAS SLDYWGQGTLVTVSSASTKGPTVKILQSICDGGGHFPPTIQLLCLVSGYTPGTIQ ITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQG HTFEDSTKKCAGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQGIRN YLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQ RYNRAPYTFGQGTKVEIKRTVAAPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQI TWLEDGOVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFE DSGKKCABold = Adalimumab Heavy ChainItalicized = LinkerUnderlined = Adalimumab Light ChainSEQ ID NO: 7 SOX6 Isoform C (Addgene, Plasmid # 142397) MSSKQATSPFACAADGEDAMTQDLTSREKEEGSDQHVASHLPLHPIMHNKPHSEELP TLVSTIQQDADWDSVLSSQQRMESENNKLCSLYSFRNTSTSPHKPDEGSRDREIMTS VTFGTPERRKGSLADVVDTLKQKKLEEMTRTEQEDSSCMEKLLSKDWKEKMERLN TSELLGEIKGTPESLAEKERQLSTMITQLISLREQLLAAHDEQKKLAASQIEKQRQQM DLARQQQEQIARQQQQLLQQQHKINLLQQQIQVQGHMPPLMIPIFPHDQRTLAAAAA AQQGFLFPPGITYKPGDNYPVQFIPSTMAAAAASGLSPLQLQKGHVSHPQINQRLKG LSDRFGRNLDTFEHGGGHSYNHKQIEQLYAAQLASMQVSPGAKMPSTPQPPNTAGT VSPTGIKNEKRGTSPVTQVKDEAAAQPLNLSSRPKTAEPVKSPTSPTQNLFP ASKTSP VNLPNKSSIPSPIGGSLGRGSSLDILSSLNSPALFGDQDTVMKAIQEARKMREQIQREQ QQQQPHGVDGKLSSINNMGLNSCRNEKERTRFENLGPQLTGKSNEDGKLGPGVIDLT RPEDAEGGATVAEARVYRDARGRASSEPHIKRPMNAFMVWAKDERRKILQAFPDM HNSNISKILGSRWKSMSNQEKQPYYEEQARLSKIHLEKYPNYKYKPRPKRTCIVDGK KLRIGEYKQLMRSRRQEMRQFFTVGQQPQIPITTGTGVVYPGAITMATTTPSPQMTS DCSSTSASPEPSLPVIQSTYGMKTDGGSLAGNEMINGEDEMEMYDDYEDDPKSDYSS ENEAPEAVSANSEQ ID NO 8: NURR1 Isoform A (Addgene, Plasmid #102363) MTKENPRSNQEESYDDNESPCVQAQYGSSPQGASPASQSYSYHSSGEYSSDFLTPEF VKFSMDLTNTEITATTSLPSFSTFMDNYSTGYDVKPPCLYQMPLSGQQSSIKVEDIQM HNYQQHSHLPPQSEEMMPHSGSVYYKPSSPPTPTTPGFQVQHSPMWDDPGSLHNFH QNYVATTHMIEQRKTPVSRLSLFSFKQSPPGTPVSSCQMRFDGPLHVPMNPEPAGSH HVVDGQTFAVPNPIRKPASMGFPGLQIGHASQLLDTQVPSPPSRGSPSNEGLCAVCG864921-5119-9043, v. 2DNAACQHYGVRTCEGCKGFFKRTVQKNAKYVCLANKNCPVDKRRRNRCQYCRFQ KCLAVGMVKEVVRTDSLKGRRGRLPSKPKSPQEPSPPSPPVSLISALVRAHVDSNPA MTSLDYSRFQANPDYQMSGDDTQHIQQFYDLLTGSMEIIRGWAEKIPGFADLPKADQ DLLFESAFLELFVLRLAYRSNPVEGKLIFCNGVVLHRLQCVRGFGEWIDSIVEFSSNL QNMNIDISAFSCIAALAMVTERHGLKEPKRVEELQNKIVNCLKDHVTFNNGGLNRPN YLSKLLGKLPELRTLCTQGLQRIFYLKLEDLVPPPAIIDKLFLDTLPF874921-5119-9043, v. 2XIII. ReferencesThe following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.Huang, T., David, L., Mendoza, V., Yang, Y., Villarreal, M., De, K., Sun, L., Fang, X., Lopez- Casillas, F„ Wrana, J. L., & Hinck, A. P. (2011). TGF- signalling is mediated by two autonomously functioning TPRI:T[3RII pairs. EMBO J 30 (2011) 1263-1276.Lee, J. C., Brien, H. J., Walton, B. L., Eidman, Z. M., Toda, S., Lim, W. A., & Brunger, J. M.(2023). Instructional materials that control cellular activity through synthetic Notch receptors. Biomaterials 297 (2023) 122099.Leibly, D. J., Arbing, M. A., Pashkov, I., DeVore, N., Waldo, G. S., Terwilliger, T. C., & Yeates, T. O. (2015). A Suite of Engineered GFP Molecules for Oligomeric Scaffolding. Structure 23 (2015) 1754-1768.Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M„ Thomson, M., & Lim, W.A. (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 164 (2016) 780-791.Muller, Y. A., Li, B., Christinger, H. W., Wells, J. A., Cunningham, B. C., & Vos, A. M. de.(1997). Vascular endothelial growth factor: Crystal structure and functional mapping of the kinase domain receptor binding site. Proceedings of the National Academy of Sciences 94 (1997) 7192-7197.Piraner, D. I., Abedi, M. H., Gonzalez, M. J. D., Chazin-Gray, A., Lin, A., Zhu, I., Ravindran, P. T., Schlichthaerle, T., Huang, B., Bearchild, T. H., Lee, D., Wyman, S., Jun, Y. W., Baker, D., & Roybal, K. T. (2025). Engineered receptors for soluble cellular communication and disease sensing. Nature 638 (2025) 805-813.Salmon, P. & Trono, D. (2007). Production and Titration of Lentiviral Vectors. Current Protocols in Human Genetics 54 (2007) 12.10.1-12.10.24.Smith, R. A. & Baglioni, C. (1987). The active form of tumor necrosis factor is a trimer. J Biol Chem 262 (1987) 6951-6954.884921-5119-9043, v. 2Varnum-Finney, B., Wu, L., Yu, M., Brashem-Stein, C., Staats, S., Flowers, D., Griffin, J. D., & Bernstein, I. D. (2000). Immobilization of Notch ligand. Delta-1, is required for induction of Notch signaling, J Cell Sci 113 (2000) 4313-4318.Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. NatBiotechnol 15 (1997) 871— 875.Lee, D., Hyun, J. H., Jung, K., Hannan, P., & Kwon, H. -B. (2017). A calcium- and light-gated switch to induce gene expression in activated neurons. Nat. Biotechnol. 35 (2017) 858- 863.Lee, D., Creed, M., Jung, K., Stefanelli, T., Wendler, D. J., Oh, W. C., Mignocchi, N. L., Liischer, C., & Kwon, H. -B. (2017). Temporally precise labeling and control of neuromodulatory circuits in the mammalian brain. Nat. Methods 14 (2017) 495-503. Lee, J. U., Shin, W., Son, J. Y., Yoo, K. -Y., & Heo, Y. -S. (2017). Molecular Basis for the Neutralization of Tumor Necrosis Factor a by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int. J. Mol. Sci. 18 (2017) 228.Oyama, S., Ebina, K., Etani, Y., Hirao, M., Kyuuma, M., Fujii, Y., Iwata, K., Ogawa, B., Hasegawa, T., Kawano, S., Nakanishi, Y., Okada, S., & Nakata, K. (2022). A novel anti-TNF-a drug ozoralizumab rapidly distributes to inflamed joint tissues in a mouse model of collagen induced arthritis. Sci. Rep. 12 (2022) 18102.Silence, K., Lauwereys, M. J., & Dreier, T. (2017). Stabilized single domain antibodies.US20170107302A1, 2017. (accessed January 20, 2025).Ward-Kavanagh, L. K., Lin, W. W., Sedy, J. R., & Ware, C. F. (2016). The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity 44 (2016) 1005-1019.Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C.A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003). Adalimumab. a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial, Arthritis Rheum. 48 (2003) 35-45.894921-5119-9043, v. 2Brien, H. J., Lee, J. C., Sharma, J., Hamann, C. A., Spetz, M. R., Lippmann, E. S., & Brunger, J. M. (2024). Templated Pluripotent Stem Cell Differentiation via Substratum-Guided Artificial Signaling. ACS Biomater. Sci. Eng. 10 (2024) 6465-6482.Brunger, J. M., Zutshi, A., Willard, V. P., Gersbach, C. A., & Guilak, F. (2017). Genome Engineering of Stem Cells for Autonomously Regulated. Closed-Loop Delivery of Biologic Drugs, Stem Cell Rep. 8 (2017) 1202-1213.Cai, J., Donaldson, A., Yang, M., German, M. S., Enikolopov, G., & lacovitti, L. (2009). The role of Lmxla in the differentiation of human embryonic stem cells into midbrain dopamine neurons in culture and after transplantation into a Parkinson’s disease model. Stem Cells Dayt. Ohio 27 (2009) 220-229.Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., Wagner, R., Lee, G. O., Antosiewicz- Bourget, J., Teng, J. M. C., & Thomson, J. A. (2011). Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8 (2011) 424-429.Chen, J., Chen, H., Li, P., Diao, H., Zhu, S., Dong, L., Wang, R., Guo, T., Zhao, J., & Zhang, J. (2011). Simultaneous regeneration of articular cartilage and subchondral bone in vivo using MSCs induced by a spatially controlled gene delivery system in bilayered integrated scaffolds. Biomaterials 32 (2011) 4793-4805.Hegarty, S. V., Sullivan, A. M., & O’Keeffe, G. W. (2013). Midbrain dopaminergic neurons:A review of the molecular circuitry that regulates their development. Dev. Biol. 379 (2013) 123-138.Khoury, M., Adriaansen, J., Vervoordeldonk, M. J. B. M., Gould, D., Chernajovsky, Y., Bigey, P., Bioquel, C., Scherman, D., Tak, P. P., Jorgensen, C., & Apparailly, F. (2007). Inflammation-inducible anti-TNF gene expression mediated by intra-articular injection of serotype 5 adeno-associated virus reduces arthritis. J. Gene Med. 9 (2007) 596-604. Kim, T. W., Piao, J.. Koo, S. Y„ Kriks, S., Chung, S. Y„ Betel, D., Socci, N. D„ Choi, S. J., Zabierowski, S., Dubose, B. N., Hill, E. J., Mosharov, E. V., Irion, S., Tomishima, M. J., Tabar, V., & Studer, L. (2021). Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. Cell Stem Cell 28 (2021) 343-355.e5.904921-5119-9043, v. 2Kriks, S., Shim, J. -W., Piao, J., Ganat, Y. M., Wakeman, D. R., Xie, Z., Carrillo-Reid, L., Auyeung, G., Antonacci, C., Buch, A., Yang, L., Beal, M. F., Surmeier, D. J., Kordower, J. H., Tabar, V., & Studer, L. (2011). Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD. Nature 480 (2011) 547-551. Pantazis, C. B., Yang, A., Lara, E., McDonough, J. A., Blauwendraat, C., Peng, L., Oguro, H., Kanaujiya, J., Zou, J., Sebesta, D., Pratt, G., Cross, E., Blockwick, J„ Buxton, P., Kinner-Bibeau, L., Medura, C., Tompkins, C., Hughes, S., Santiana, M., Faghri, F., Nalls, M. A., Vitale, D., Ballard, S., Qi, Y. A., Ramos, D. M., Anderson, K. M., Stadler, J., Narayan, P., Papademetriou, J., Reilly, L., Nelson, M. P., Aggarwal, S., Rosen, L. U., Kirwan, P., Pisupati, V., Coon, S. L., Scholz, S. W„ Priebe, T., Ottl, M., Dong, J., Meijer, M„ Janssen, L. J. M., Lourenco, V. S., Kant, R. van der., Crusius, D., Paquet, D., Raulin, A. -C., Bu, G., Held, A., Wainger, B. J., Gabriele, R. M. C., Casey, J. M., Wray, S., Abu-Bonsrah, D., Parish, C. L., Beccari, M. S., Cleveland, D. W., Li, E., Rose, I. V. L., Kampmann, M., Aristoy, C. Calatayud., Verstreken, P., Heinrich, L., Chen, M. Y., Schule, B., Dou, D., Holzbaur, E. L. F., Zanellati, M. C., Basundra, R., Deshmukh, M., Cohen, S., Khanna, R., Raman, M., Nevin, Z. S., Matia, M., Lent, J. Van., Timmerman, V., Conklin, B. R., Chase, K. Johnson., Zhang, K., Funes, S., Bosco, D. A., Erlebach, L., Welzer, M., Kronenberg-Versteeg, D., Lyu, G., Arenas, E., Coccia, E., Sarrafha, L., Ahfeldt, T., Marioni, J. C., Skarnes, W. C., Cookson, M. R., Ward, M. E., & Merkle, F. T. (2022). A reference human induced pluripotent stem cell line for large-scale collaborative studies. Cell Stem Cell 29 (2022) 1685-1702. e22.Santos, M. T. Alves dos. & Smidt, M. P. (2011). Enl and Wnt signaling in midbrain dopaminergic neuronal development. Neural Develop. 6 (2011) 23.Zhu, I., Liu, R., Garcia, J. M., Hyrenius-Wittsten, A., Piraner, D. I., Alavi, J., Israni, D. V., Liu, B., Khalil, A. S., & Roybal, K. T. (2022). Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185 (2022) 1431-1443.el6.Addgene, Plasmid # 142397Addgene, Plasmid #102363914921-5119-9043, v. 2
Claims
WHAT IS CLAIMED IS:
1. An engineered iPSC-derived mDA progenitor cell expressing one or more artificial TNF-sensitive receptors, activation of which results in expression of a transgene.
2. The engineered iPSC-derived mDA progenitor cell of claim 1, wherein the transgene encodes a TNF antagonist.
3. The engineered iPSC-derived mDA progenitor cell of claim 1 or claim 2, wherein the artificial TNF-sensitive receptor is a Regulated Intramembrane Proteolysis (RIP) receptor.
4. The engineered iPSC-derived mDA progenitor cell of claim 3, RIP receptor is a synthetic Notch (synNotch) receptor.
5. The engineered iPSC-derived mDA progenitor cell of claim 3, wherein the RIP receptor is a synthetic intramembrane proteolysis receptor (SNIPR).
6. The engineered iPSC-derived mDA progenitor cell of any one of claims 2-5, wherein the TNF antagonist comprises soluble TNF receptor 1 (sTNFRl) or an anti-TNF binding domain.
7. The engineered iPSC-derived mDA progenitor cell of claim 6, wherein the anti-TNF binding domain comprises a TNF-binding domain derived from ozoralizumab, certolizumab or adalimumab.
8. The engineered iPSC-derived mDA progenitor cell of any one of claims 1-5, wherein the transgene encodes a fate-stabilizing factor.
9. The engineered iPSC-derived mDA progenitor cell of claim 8, wherein the fatestabilizing factor comprises a WNT ligand, NURR1, or SOX6.
10. The engineered iPSC-derived mDA progenitor cell of any one of claims 1-9, further comprising an artificial receptor activated by a ligand integrated in a hydrogel.924921-5119-9043, v.
211. The engineered iPSC-derived mDA progenitor cell of claim 10, wherein the ligand comprises GFP, dimeric GFP, or a GFP-derived ligand.
12. The engineered iPSC-derived mDA progenitor cell of claim 10 or claim 11, wherein the artificial receptor activated by the ligand integrated in the hydrogel comprises an extracellular domain comprising a GFP-binding agent.
13. The engineered iPSC-derived mDA progenitor cell of claim 12, wherein the GFP- binding agent comprises LaG16 or LaG17.
14. The engineered iPSC-derived mDA progenitor cell of any one of claims 10-13, wherein activation of the artificial receptor by the ligand integrated in the hydrogel results in expression of a fate-stabilizing factor.
15. An implantable device comprising a plurality of the engineered iPSC-derived mDA progenitor cells according to any one of claims 1-14.
16. The implantable device of claim 15, wherein the device comprises a hydrogel associated with the plurality of engineered iPSC-derived mDA progenitor cells.
17. The implantable device of claim 16, wherein the hydrogel associated with the plurality of engineered iPSC-derived mDA progenitor cells comprises the plurality of engineered iPSC-derived mDA progenitor cells encapsulated within, seeded into, or entrapped within the hydrogel.
18. The implantable device of claim 16 or claim 17, wherein the hydrogel comprises a granular hydrogel comprising hydrogel microparticles.
19. The implantable device of claim 18, wherein the plurality of engineered iPSC-derived mDA progenitor cells is seeded into or entrapped within an interstitial pore network of the granular hydrogel microparticles.
20. The implantable device of any one of claims 16-1 , wherein the hydrogel comprises a ligand integrated in the hydrogel, wherein the ligand is conjugated to, immobilized on, embedded in, or entrapped within the hydrogel.934921-5119-9043, v.
221. The implantable device of claim 20, wherein the ligand comprises GFP, dimeric GFP, or a GFP-derived ligand.
22. The implantable device of claim 20 or claim 21, wherein the ligand activates an artificial receptor expressed by the engineered iPSC-derived mDA progenitor cells.
23. The implantable device of any one of claims 16-22, wherein the hydrogel has a size or ligand functionalization selected to enhance viability of the engineered iPSC-derived mDA progenitor cells after transplantation and activation of a RIP receptor expressed by the engineered iPSC-derived mDA progenitor cells.
24. The implantable device of any one of claims 16-23, wherein the hydrogel is degradable.
25. The implantable device of claim 24, wherein degradation of the hydrogel reduces activation of the artificial receptor activated by the ligand integrated in the hydrogel.
26. The implantable device of claim 24 or claim 25, wherein degradation of the hydrogel is timed to correspond to maturation of the engineered iPSC-derived mDA progenitor cells.
27. A method of delivering the engineered iPSC-derived mDA progenitor cell of any one of claims 1-14 to a subject comprising implanting the implantable device of any one of claims 15-26 into said subject.
28. The method of claim 27, wherein said subject suffers from Parkinson’s disease.944921-5119-9043, v. 2
